

CURRICULUM VITAE
Geralyn M. Lambert-Messerlian, PhD, FAACC, HCLD (NRCC)

Business Address: Women and Infants Hospital
 Department of Pathology and Laboratory Medicine
 Division of Medical Screening and Special Testing
 70 Elm Street, 2nd floor
 Providence, Rhode Island 02903

Telephone: 401-453-7793
 Fax: 401-276-7882
 e-mail: gmesserlian@wihri.org

EDUCATION

1982-1986 B.A. Psychobiology: Wheaton College, Norton MA
Awards: Magna cum laude, Julia Lange and Phi Beta Kappa Scholarships, Tri Beta Biological and Phi Beta Kappa Honor Societies

1986-1991 Ph.D. Biology (Reproductive Endocrinology): Boston University, MA
Awards: Belamarich Dissertation Award, New England Endocrinology Conference Student Award

2006 M.A. Brown University (*ad eundem*)

POSTGRADUATE TRAINING AND EDUCATION

1991-1994 Massachusetts General Hospital/ Harvard University
 Reproductive Endocrine Unit
 Post-doctoral Research Fellow

2010 Clinical Laboratory Leadership and Management Certificate
 American Association of Clinical Chemistry

2014 Concepts in Molecular Biology
 Michigan State University

2014 Fundamentals of Molecular Pathology Certificate
 American Association of Clinical Chemistry

2020 Statistical Methods for Clinical Laboratorians Certificate
 American Association of Clinical Chemistry

2021- Higher Education Administration Certificate
 Northeastern University

POSTGRADUATE HONORS AND AWARDS

2013	Jacob Canick Translational Research Award Alpert Medical School at Brown University
2010	Nelson Fausto Teaching Award Alpert Medical School at Brown University
2015	Outstanding Speaker Award American Association for Clinical Chemistry
2016	Outstanding Author in Obstetrics and Gynecology Up to Date
2016	Outstanding Abstract award Endocrinology Division American Association for Clinical Chemistry

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

1996-2016	State of Rhode Island Clinical Lab Scientist
2001-2007 2011-2020	New York State Department of Health Laboratory Director
2009-present	High Complexity Lab Director (HCLD) National Registry of Certified Chemists (NRCC)

ACADEMIC APPOINTMENTS

1994-1995	Harvard University Instructor in Medicine
1995-1999	Alpert Medical School of Brown University Pathology and Laboratory Medicine Assistant Professor (Research)
2000-2004	Alpert Medical School of Brown University Pathology and Laboratory Medicine Assistant Professor
2005-2010	Alpert Medical School of Brown University Pathology and Laboratory Medicine Associate Professor
2011-	Alpert Medical School of Brown University Pathology and Laboratory Medicine Professor
2016-	Alpert Medical School of Brown University Obstetrics and Gynecology Professor

2021-2022 Undergraduate Academic Advisor
Brown University

2022- Vice Chair for Clinical Faculty Development
Department of Pathology and Laboratory Medicine
Alpert Medical School at Brown University

HOSPITAL APPOINTMENTS

1994-1995 Massachusetts General Hospital
Reproductive Endocrine Unit
Assistant in Biochemistry

1995-1999 Women and Infants Hospital
Division of Prenatal and Special Testing
Assistant Director

2000-2012 Women and Infants Hospital
Division of Medical Screening and Special Testing
Associate Director

2010- Center for Biomarkers and Emerging Technologies (CBET)
Department of Obstetrics and Gynecology
Director

2010-2012 Women and Infants Hospital
Research Steering Committee (S2N/T2)

2013-2016 Women and Infants Hospital
Library Committee for Medical Staff Office

2013-2020 Women and Infants Hospital
Division of Medical Screening and Special Testing
Director

2014-2020 Women and Infants Hospital
Division of Chemistry
Assistant Director

2021- Care New England
Chemistry and Special Testing
Director

OTHER APPOINTMENTS

1999- Journal Reviewer - Journal of Clinical Endocrinology and Metabolism
2001- Journal Reviewer - Hormones and Behavior

2003-2005 Editorial Board
2022-2024 Journal of Clinical Endocrinology and Metabolism

2005-2015 Journal Reviewer – Prenatal Diagnosis
Journal Reviewer – Journal of Medical Screening

2007-	Journal Reviewer – Clinica Chimica Acta (ad hoc)
2008-	Journal Reviewer – Fertility and Sterility
2009-	Journal Reviewer – European Journal of Obstetrics and Gynecology and Reproductive Biology
2009-	Fellow of the National American Association of Clinical Chemistry (FAACC)
2015-	<u>Editorial Board</u> Prenatal Diagnosis
2016-	<u>Section Editor</u> Reproductive Biology and Endocrinology
2019-	<u>Editorial Board</u> Journal of Medical Screening
2021-	Advisory Board Office of Women in Medicine and Science (OWIMS) Alpert Medical School at Brown University
2022-2023	<u>Associate Editor</u> Human Reproduction

LOCAL COMMITTEES

1996-1999	RI Department of Health Healthy Mothers/Healthy Babies Genetic Services Task Force
1997-	Women and Infants Hospital Hospital Corporation Member
1999-2002	RI Folic Acid Council March of Dimes
2001-	Birth Defects Surveillance Advisory Committee RI Department of Health
2001-2005	Chair Initiative in Human Genetics Women & Infants Hospital
2002-2006	Executive Round Table Women & Infants Hospital
2007-2018	Institutional Review Board for Human Studies Women and Infants Hospital
2015-2017	Faculty Promotions Committee Alpert Medical School at Brown University
2017-	Committee Chair Pathology Faculty Promotions

Alpert Medical School at Brown University

2022- Co-Chair
Communications Committee
Department of Pathology

REGIONAL COMMITTEES

2001-2002 Boston Fertility Society
Educational Meeting Organizational Committee

INTERNATIONAL COMMITTEES

2007-2011 Women in Endocrinology
Communications Committee (Chair, 2007-2010)

2011 Abstract Reviewer
Endocrine Society

2013-2016 Women in Endocrinology
Secretary-Treasurer

2016-2021 Women in Endocrinology
Awards Committee

2021-2024 American Association for Clinical Chemistry
Endocrinology Division
Secretary

2023 Abstract Reviewer
Endocrine Society

MEMBERSHIP IN SOCIETIES

American Association for Clinical Chemistry
American Society for Reproductive Medicine
Endocrine Society
European Society for Human Reproduction and Embryology
International Down Syndrome Screening Group
International Society Prenatal Diagnosis
Medical Screening Society
Women in Endocrinology

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Villars TA, Erskine MS, Lambert GM, Jacobson D, Weaver CE and Baum MJ. Endocrine correlates of mating induced reductions in estrous behavior in an induced ovulator, the ferret. Horm Behav 24: 198-214, 1990.

2. Lambert GM, Erskine MS and Baum MJ. Effect of naloxone on the pulsatile secretion of luteinizing hormone in gonadectomized male and female ferrets. J Neuroendocrinol 2(5): 701-705, 1990.

3. Lambert GM and Baum MJ. Reciprocal relationships between pulsatile androgen secretion and the expression of mating behavior in adult male ferrets. *Horm Behav* 25: 382-393, 1991.
4. Lambert GM, Rubin BS and Baum MJ. Sexual dimorphism in the effects of mating on *in vitro* release of LHRH from the ferret medio-basal hypothalamus. *Physiol Behav* 52: 809-813, 1992.
5. Lambert GM, Rubin BS and Baum MJ. Sex difference in the effect of mating on *c-fos* expression in luteinizing hormone releasing hormone neurons of the ferret forebrain. *Endocrinology* 131(3): 1473-1480, 1992.
6. Lambert-Messerlian GM, Isaacson KI, Crowley WF Jr, Sluss PM and Schneyer AL. Human follicular fluid contains pro- and C-terminal immunoreactive alpha-inhibin precursor proteins. *J Clin Endocrinol Metab* 78(2): 433-439, 1994.
- *7. Lambert-Messerlian GM, Hall JE, Sluss PM, Taylor AE, Martin KA, Groome NP, Crowley WF Jr and Schneyer AL. Relatively low levels of dimeric inhibin in men and women with PCOS using a specific two-site ELISA. *J Clin Endocrinol Metab*, 79(1): 45-50, 1994.
8. Lambert-Messerlian GM, Crowley WF Jr and Schneyer AL. Extragonadal alpha inhibin precursor proteins circulate in human male serum. *J Clin Endocrinol Metab*, 80(10): 3043-3049, 1995.
9. Good TEM, Weber PSD, Ireland JLH, Pulsaki J, Padmanabhan V, Schneyer AL, Lambert-Messerlian G, Ghosh BR, Miller WL, Groome N and Ireland JJ. Isolation of nine different biologically and immunologically active molecular variants of bovine follicular inhibins. *Biol Reprod*, 53: 1478-1488 1995.
10. Schneyer AL, Hall HA, Lambert-Messerlian G, Wang QF, Sluss P and Crowley WF Jr. Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically. *Endocrinology*, 137: 240-247, 1996.
11. Seifer DB, Lambert-Messerlian GM, Canick JA, Frishman GN and Schneyer AL. Serum inhibin levels are lower in ectopic than intrauterine spontaneously conceived pregnancies. *Fertil Steril*, 65(3): 667-669, 1996.
12. Seifer DB, Gardiner A, Lambert-Messerlian G and Schneyer A. Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. *J Clin Endocrinol Metab*, 81(2): 736-739, 1996.
- *13. Lambert-Messerlian GM, Palomaki GE, Schneyer AL and Canick JA. Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor and activin in Down syndrome pregnancy, *J Med Screen*, 3: 58-62, 1996.
14. Zheng W, Sung CJ, Hanna I, Depetros G, Lambert-Messerlian G, Steinhoff M and Lauchlan SC. Alpha and betaA subunits of inhibin/activin as sex-cord-stromal differentiation markers. *Int J Gynecol Pathol*, 16: 263-271, 1997.
15. Seifer DB, Lambert-Messerlian GM, Hogan JW, Gardiner AC, Blazar AS and Berk CA. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. *Fertil Steril*, 67: 110-114, 1997.
16. Lambert-Messerlian GM, Zheng W, Steinhoff M, Gajewski WH, Seifer DB and Schneyer AL. Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. *Gynecol Oncol*, 65: 512-516, 1997.

17. Welt CK, Martin KA, Taylor AE, Lambert-Messerlian GM, Crowley WF Jr., Smith JA, Schoenfeld DA and Hall JE. Frequency modulation of follicle-stimulating hormone (FSH) during the luteal-follicular transition: evidence for FSH control of inhibin B in normal women. *J Clin Endocrinol Metab*, 82: 2645-2652, 1997.
18. Welt CK, Lambert-Messerlian GM, Zheng W, Sluss P, Crowley WF Jr. and Schneyer AL. The presence of activin, inhibin and follistatin in epithelial ovarian carcinoma. *J Clin Endocrinol Metab* 82: 3720-3727, 1997.
19. Lambert-Messerlian G, Taylor A, Leykin L, Isaacson K, Toth T, Chang Y and Schneyer A. Characterization of intrafollicular steroid hormones, inhibin and follistatin in women with and without polycystic ovarian syndrome following gonadotropin hyperstimulation. *Biol Reprod*, 57:1211-1216, 1997.
20. Lambert-Messerlian GM, Canick JA, Melegos DN and Diamandis EP. Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome. *Clin Chem*, 44:205-208, 1998.
21. Lambert-Messerlian G, Luisi S, Florio P, Mazza V, Canick J and Petraglia F. Second trimester levels of maternal serum total activin A and placental alpha and beta A subunit messenger ribonucleic acid in Down syndrome pregnancy. *Eur J Endocrinol*, 138: 425-429, 1998.
22. Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Zhang Z, Ying S, Schneyer AL, Lauchlan SC and Felix JC. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. *Gynecol Oncol*, 69: 23-31, 1998.
23. Lambert-Messerlian GM, Saller DN Jr, Tumber MB, French CA, Peterson CJ and Canick, JA. Second trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. *Prenat Diagn*, 18: 1061-1067, 1998.
24. Lambert-Messerlian GM, Saller DN Jr, Tumber MB, French CA, Peterson CJ and Canick JA. Second-trimester maternal serum progesterone levels in Turner syndrome with and without hydrops and in trisomy 18. *Prenat Diagn*, 19: 476-479, 1999.
25. Silver HM, Lambert-Messerlian GM, Star JA, Hogan J and Canick JA. Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic and non-proteinuric gestational hypertensive pregnancy. *Am J Obstet Gynecol*, 180:1131-1137, 1999.
26. Lambert-Messerlian GM, Depasquale S, Maybruck WM, Steinhoff MM and Gajewski W. Secretion of activin A in recurrent epithelial ovarian carcinoma. *Gynecol Oncol*, 74: 93-97, 1999.
27. Phipps MG, Hogan JW, Peipert JF, Lambert-Messerlian GM, Canick JA and Seifer DB. Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. *Obstet Gynecol*, 95:227-31, 2000.
28. Lambert-Messerlian GM, Silver H, Petraglia F, Luisi S, Plaino L, Maybruck W, Hogge WA and Canick JA. Second trimester maternal serum levels of inhibin A and human chorionic gonadotropin as markers for prediction of preeclampsia. *J Soc Gynecol Investig*, 7:170-174, 2000.
29. Rausch DN, Lambert-Messerlian GM and Canick JA. Participation in maternal serum screening following screen positive results in a previous pregnancy. *J Med Screen*, 7:3-6, 2000.

30. Fujiwara T, Lambert-Messerlian G, Sidis Y, Leykin L, Isaacson K, Toth T and Schneyer A. Analysis of follicular fluid concentrations and granulosa cell mRNA levels for the inhibin/activin/follistatin system: relationship to oocyte/embryo characteristics. *Fertil Steril*, 74:348-355, 2000.
31. Lambert-Messerlian GM, Palomaki GE and Canick JA. Second trimester levels of maternal serum inhibin A in pregnancies affected by fetal neural tube defects. *Prenat Diagn*, 20:680-682, 2000.
32. Dzik A, Lambert-Messerlian G, Izzo VM, Soares JB, Pinotti JA and Seifer DB. Inhibin B response to EFORT is associated with outcome of oocyte retrieval in the subsequent IVF cycle. *Fertil Steril*, 74:1114-1117, 2000.
33. Goodwin KM, Sweeney PJ, Lambert-Messerlian GM and Canick JA. High maternal serum levels of inhibin A following the loss of one fetus in a twin pregnancy. *Prenat Diagn*, 20:1015-1017, 2000.
34. Schneyer AL, Fujiwara T, Fox J, Welt CK, Messerlian GM and Taylor AE. Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: relationship to circulating hormone concentrations. *J Clin Endocrinol Metab*, 85: 3319-3330, 2000.
35. Yamamoto H, Lambert-Messerlian GM, Silver HS, Kudo R, Kellner LH and Canick JA. Maternal serum levels of type I and type III procollagen peptides in preeclamptic pregnancy. *J Matern Fetal Med*, 10: 40-43, 2001.
36. Knight GJ, Palomaki GE, Neveux LM, Haddow JE and Lambert-Messerlian GM. Clinical validation of a new dimeric inhibin A assay suitable for second trimester Down's syndrome screening. *J Med Screen*, 8: 2-7, 2001.
37. Fujiwara T, Sidis Y, Welt C, Lambert-Messerlian G, Fox J, Taylor A and Schneyer A. Dynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles. *J Clin Endocrinol Metab*, 86:4206-4215, 2001.
38. Malee MP, Verma A, Messerlian G, Tucker R, Vohr, BR. Association between maternal and child leptin levels 9 years after pregnancy complicated by gestational diabetes. *Horm Metab Res*, 34:212-216, 2002.
39. DePasquale S, Lambert-Messerlian G, Quddus MR, Campbell I, Steinhoff M, Gajewski W, Granai C, Tantravahi U. Molecular analysis of inhibin A and activin A subunit gene loci in epithelial ovarian cancer. *Int J Gynecol Cancer*, 12:443-447, 2002.
40. Florio P, Ciarmela P, Luisi S, Mercanti V, Lambert-Messerlian G, Severi FM, Petraglia F. Pre-eclampsia with fetal growth restriction: placental and serum activin-A and inhibin-A levels. *Gynecol Endocrinol*, 16:1-8, 2002.
41. Silver HM, Lambert-Messerlian GM, Reis FM, DiBlasio AM, Petraglia F, Canick JA. The mechanisms of increased maternal serum total activin A and inhibin A in preeclampsia. *J Soc Gynecol Investig*, 9:308-12, 2002.
42. Lee T, LeShane ES, Messerlian GM, Canick JA, Farina A, Heber WW, Bianchi DW. Down syndrome and cell-free fetal DNA in archived maternal serum. *Am J Obstet Gynecol*, 187:1217-21, 2002.
43. Thirunavukarasu PP, Lambert-Messerlian G, Robertson DM, Dawson G, Canick J, Wallace EM. Molecular weight forms of inhibin A, inhibin B and pro-alphaC in maternal serum, amniotic fluid and placental extracts of normal and Down syndrome pregnancies. *Prenat Diagn*, 22 (12):1086-92, 2002.

44. Wataganara T, LeShane E, Farina A, Messerlian GM, Lee T, Canick JA, Bianchi DW. Maternal serum cell-free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18. *Hum Genet*, 112:204-8, 2003.
45. Farina A, LeShane E, Lee T, Lambert-Messerlian GM, Canick JA, Bianchi DW. Performance of cell-free fetal DNA as a second trimester maternal serum marker of Down syndrome pregnancy. *Clin Chem*, 49(2): 2003.
46. Seifer DB, Lambert-Messerlian G, Schneyer AL. Ovarian brain-derived neurotrophic factor (BDNF) is present in follicular fluid from normally cycling women. *Fertil Steril*, 79(2): 451-2, 2003.
47. Plevyak MP, Lambert-Messerlian GM, Farina A, Groome NP, Silver HM. Concentrations of serum total activin A and inhibin A in preterm and term labor patients: a cross sectional study. *J Soc Gynecol Investig*, 1-:231-6, 2003.
48. Lambert-Messerlian GM, Pinar H, Laprade E, Tantravahi U, Schneyer AL, Canick JA. Inhibins and activins in human fetal abnormalities. *Mol Cell Endocrinol*, 225(1-2):101-8, 2004.
49. Wataganara T, Peter I, Messerlian GM, Borgatta L, Bianchi DW. Inverse correlation between maternal weight and second trimester circulating cell-free fetal DNA levels. *Obstet Gynecol*, 104(3):545-50, 2004.
50. Lambert-Messerlian GM, Canick JA. Placenta growth factor levels in second trimester maternal serum from pregnancies affected with Down syndrome and in prediction of preeclampsia. *Prenat Diagn*, 24: 876-880, 2004.
51. Lambert-Messerlian GM, Pinar H, Rubin L, Canick JA. Second trimester serum markers in pregnancy with a coexisting mole. *Pediatr Dev Pathol*, 8(2); 230-234, Apr 2005.
52. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Hackshaw AK, Lambert-Messerlian G, D'Alton ME for the FASTER Research Consortium* First and Second Trimester Evaluation of Risk for Fetal Aneuploidy (FASTER): Principal Results of the NICHD Multicenter Down Syndrome Screening Study. *N Engl J Med*, 353(19): 2001-11, Nov 2005.
53. Pan P, Peter I, Lambert-Messerlian GM, Canick JA, Bianchi DW, Johnson KL. Cell-free fetal DNA levels in pregnancies conceived by in vitro fertilization. *Mol Hum Reprod*, 20(11): 3152-3156, Nov 2005.
54. Welt CK, Taylor AE, Fox J, Messerlian GM, Adams JM, Schneyer AL. Follicular arrest in polycystic ovary syndrome is associated with deficient inhibin A and B biosynthesis. *J Clin Endocrinol Metab* 90: 5582-5587, Oct 2005.
55. Dugoff L, Hobbins JC, Malone FD, Canick JA, Lambert-Messerlian G, Porter TF, Luthy D, Comstock CH, Saade G, Eddleman K, Merkatz I, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Vidaver J, D'Alton ME for the FASTER Trial Research Consortium. The Quad screen as a predictor of adverse pregnancy outcome. A population-based screening study. *Obstet Gynecol*, 106: 260-7, Aug 2005.
56. Silberstein T, MacLaughlin DT, Shai I, Trimarchi JB, Lambert-Messerlian G, Seifer DB, Keefe DL, Blazar A. Mullerian inhibitory substance levels at the time of hCG administration in IVF cycles predict both ovarian reserve and embryo quality. *Hum Reprod*, 21(1)159-163, Jan 2006.

57. Lambert-Messerlian G, Eklund E, Malone F, Canick J, Palomaki G, D'Alton M and the FASTER research consortium. Stability of first and second trimester serum markers after shipment. *Prenat Diagn*, 26(1):17-21, Jan 2006.
58. Lambert-Messerlian GM, Harlow BL. The influence of depression, body mass index and smoking on serum inhibin B levels in late reproductive aged women. *J Clin Endocrinol Metab*, 91:1496-1500, Mar 2006.
59. Farina A, Lambert-Messerlian GM, Canick JA, Banzola I, Carletti A, Concu M, Tempesta A, Gabrielli S, Morano D, Rizzo N. Total activin A in maternal blood as a marker of preterm delivery in low-risk asymptomatic patients. *Prenat Diagn* 26: 277-81, Mar 2006.
60. Lambert-Messerlian G, Dugoff L, Vidaver J, Canick JA, Malone FD, Ball RH, Comstock CH, Nyberg DA, Saade G, Eddleman K, Klugman S, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME. First and second trimester Down syndrome screening markers in pregnancies achieved through assisted reproductive technologies (ART): A FASTER trial study. *Prenat Diagn*, 26:672-678, Aug 2006.
61. Palomaki GE, Lambert-Messerlian GM, Canick JC. A summary analysis of Down syndrome markers in the late first trimester. *Adv Clin Chem*, 43;177-210. Review. 2007.
62. Seifer DB, Golub ET, Lambert-Messerlian GM, Springer G, Holman S, Moxley M, Cejtin H, Nathwani N, Anastos K, Minkoff H, Greenblatt RM. Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women. *Fertil Steril*, Dec:88(6):1645-52, 2007
63. Lambert-Messerlian GM, Eklund E, Pinar H, Tantravahi U, Schneyer AL. Activin subunit and receptor expression in normal and cleft human fetal palate tissues. *Pediatr Dev Pathol*, Nov-Dec 10(6):436-45, 2007.
64. Nagalla SR, Canick JA, Lambert-Messerlian GM, Jacob T, Schneider KA, Reddy AP, Thomas A, Dasari S, Lu X, Lapidus JA, Gravett MG, Roberts CT, Luthy D, Malone FD, D'Alton ME, and the First and Second Trimester Evaluation of Risk (FASTER) Research Consortium. Proteomic analysis of first and second trimester maternal serum in Down syndrome: identification of novel protein biomarkers. *J Proteome Res*, 6(4):1245-57, 2007.
65. Plante BJ, Phipps MG, Blume JD, Lambert-Messerlian G, Shackelton R, Canick J. A multiple marker model to predict pregnancy viability when progesterone is indeterminate. *J Reprod Med*, 53:243–249, Apr 2008.
66. Merhi ZO, Messerlian GM, Minkoff H, Eklund EE, Macura J, Feldman J, Rodriguez C, Seifer DB. Comparison of serum and plasma measurements of mullerian inhibiting substance. *Fertil Steril*, 89;1836-7, Jun 2008.
67. G Lambert-Messerlian, M McClain, JE Haddow, GE Palomaki, JA Canick, J Cleary-Goldman, FD Malone, RH Ball, DA. Nyberg, SJ Gross, ME D'Alton, for the FASTER Research Consortium. First and second trimester thyroid hormone reference data in pregnant women: A FASTER (First and Second Trimester Evaluation of Risk for Fetal Aneuploidy) trial study. *Am J Obstet Gynecol*, 199; 62e1-e6, Jul 2008.
68. Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Tripp T, Bianchi DW, D'Alton ME; First and Second Trimester Evaluation of Risk (FASTER) Research

Consortium. First- and second-trimester screening: detection of aneuploidies other than Down syndrome. *Obstet Gynecol. Sep*; 110 (3):651-7, 2007

69. McClain M, Lambert-Messerlian G, Haddow JE, Palomaki GE, Canick JA, Cleary Goldman J, Malone FD, Porter FT, Nyberg DA, Bernstein P, D'Alton ME for the FaSTER Research Consortium* Sequential first and second trimester TSH, free T4, and thyroid antibody measurements in women with known hypothyroidism: A FaSTER (First and Second Trimester Evaluation of Risk for Fetal Aneuploidy) trial study. *Am J Obstet Gynecol. Aug*; 199(2):129 2008.

70. Palomaki GE, Neveux LM, Donnenfeld A, Lee JES, McDowell G, Canick JA, Summers A, Lambert-Messerlian G, Kellner LH, Zebelman A, Haddow JE. Quality assessment of routine nuchal translucency measurements: A North American laboratory perspective. *Genet Med* 10 (Feb):131-8, 2008.

71. Urato AC, Peter I, Canick J, Lambert-Messerlian G, Pulkkinen A, Knight G, Jeong Y-J, Johnson K, Bianchi DW. Smoking in Pregnancy is Associated with Increased Total Maternal Serum Cell-free DNA Levels. *Prenat Diagn, Mar* 28(3): 186-90, 2008.

72. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, Disilvestro P, Granai CO, Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. *Gynecol Oncol* 108: 402-8, Feb 2008.

73. Lambert-Messerlian GM, Palomaki GE, Canick JA. Inhibin A measurement using an automated assay platform. *Prenat Diagn* 28(5):399-403, 2008.

74. Haddow JE, McClain MM, Lambert-Messerlian G, Palomaki GE, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, and D'Alton ME for the FaSTER Research Consortium Variability in TSH Suppression by hCG During Early Pregnancy: A FaSTER (First and Second Trimester Evaluation of Risk for Fetal Aneuploidy) trial study. *J Clin Endocrinol Metab. Sep*; 93(9):3341-7, 2008.

75. Cleary-Goldman J, Malone FD, Lambert-Messerlian G, Sullivan L, Canick J, Porter F, Luthy D, Gross S, Bianchi DW, D'Alton ME for the FASTER Consortium. Maternal thyroid hypofunction and pregnancy outcome. *Obstet Gynecol*, 112 (1); 85-92, 2008.

76. Myers G, Lambert-Messerlian G and Sigman M. Inhibin B reference data for fertile men in Northeast America. *Fertil Steril, Dec*; 92(6):1920-3, 2009.

77. Mehri Z, Minkoff H, Messerlian G, Macura J, Feldman J, Seifer DB. Plasma Brain-derived neurotropic factor in women after bariatric surgery: A pilot study. *Fertil Steril* 91(4 Suppl):1544-8, 2009.

78. Seifer DB, Golub ET, Lambert-Messerlian G, Benning L, Anastos K, Watts DH, Cohen MH, Karim R, Young MA, Minkoff H, Greenblatt RM. Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. *Fertil Steril Nov*; 92(5):1674-8, 2009.

79. D'Alton ME, Cleary-Goldman J, Lambert-Messerlian G, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Dukes K, Canick JA, Malone FD. Maintaining quality assurance for nuchal translucency sonography: Lessons learned from the FaSTER trial. *Ultrasound Obstet Gynecol*, 33:142-6, 2009.

80. Lambert-Messerlian G, Palomaki GE, Canick JA. Adjustment of serum markers in first trimester screening. *J Med Screen*, 16:102-3, 2009.

81. Lambert-Messerlian, G, Palomaki GE, Neveux LM, Friedman A, Rosene-Montella K, Canick JA.

Early onset preeclampsia and second trimester serum markers. *Prenat Diagn*, Dec;29(12):1109-17, 2009.

82. Palomaki GE, Knight GJ, Lambert-Messerlian GM, Canick JA, Haddow JE. Four Years' Experience with an Inter-laboratory Comparison Program Involving First Trimester Markers of Down Syndrome. *Archives of Pathology & Laboratory Medicine*. Nov;134(11):1685-91, 2010.

83. Haddow JE, Cleary-Goldman J, McClain M, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, Porter TF, Nyberg DA, Bernstein P, and D'Alton ME for the FaSTER Research Consortium*. Thyroperoxidase and thyroglobulin antibodies in early pregnancy and pre-term delivery. *Obstet Gynecol*. Ju First and second trimester thyroid hormone reference data in pregnant women I 116(1):58-62, 2010

84. Vora NL, Johnson KL, Lambert-Messerlian G, Tighiouart H, Peter I, Urato AC, and Bianchi DW. Relationships between cell-free DNA and maternal serum marker levels in the first and second trimesters of pregnancy. *Obstet & Gynecol* *Obstet Gynecol*. Sep; 116(3):673-678, 2010

85. Lambert-Messerlian G, Palomaki GE, Canick JA. Examination of the PAPP-A assay on the Beckman Coulter Access platform: suitability for use in first trimester Down syndrome screening. *J Med Screen*, 17(3):109-13 2010.

86. Sprawka N, Lambert-Messerlian G, Palomaki GE, Eklund EE and Canick JA. Maternal serum alpha-fetoprotein levels in women with pre-gestational diabetes. *Prenat Diagn*, Mar 31(3):282-5, 2011.

87. Haddow JE, McClain MR, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, Porter TF, Nyberg DA, Bernstein PS, D'Alton ME; for the First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium. Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption. *Obstet Gynecol*. Feb; 117(2, Part 1):287-292, 2011

88. Lambert-Messerlian G, Roberts MB, Urlacher S, Ah-Ching J, Vial S, Urbanek M and McGarvey ST First assessment of menstrual cycle function and reproductive endocrine status in Samoan women. *Hum Reprod*, Sep;26(9):2518-24, 2011.

89. Blazar AS, Lambert-Messerlian G, Hackett R, Krotz S, Carson SA, Robins, JC. Use of in-cycle anti-mullerian hormone levels to predict cycle outcome. *Am J Obstet Gynecol*, Sep;205(3):223, 2011.

90. Nelson, HH, Almquist, LM, LaRocca, JL, Plaza, SL, Lambert-Messerlian, G, Sugarbaker, DJ, Bueno, R, Godleski, JJ, Marsit, CM, Christensen, BC, Kelsey, KT. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma. *Epigenetics*, Aug; 6:1029-34, 2011.

91. Haddow JE, Neveux LM, Palomaki GE, Lambert-Messerlian G, Canick JA, Grenache DG, Lu J. The relationship between PTH and 25-Hydroxy vitamin D early in pregnancy. *Clin Endocrinol (Oxf)*. Sep; 75(3):309-14, 2011

92. Zhang J, Lambert-Messerlian G, Palomaki GE, Canick JA. Impact of smoking on maternal serum markers and prenatal screening in the first and second trimesters. *Prenat Diagn*. Jun; 31(6):583-8, 2011.

93. Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. *Int J Gynecol Cancer*. Oct; 21(7):1185-90, 2011.

94. Cash HL, McGarvey ST, Houseman EA, Marsit CJ, Hawley NL, Lambert-Messerlian GM, Viali S, Tuitele J, Kelsey KT. Cardiovascular disease risk factors and DNA methylation at the LINE-1 repeat region in peripheral blood from Samoan Islanders. *Epigenetics*, Oct 1; 6(10), 2011.
95. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. *Genet Med*. Oct 14; 913-20, 2011.
96. Kipp J, Lambert-Messerlian G, Eklund E, Rodriguez G, Demczuk M, Gundogan F. Expression of transcription factors controlling alpha inhibin gene expression in placental tissues from pregnancies affected by fetal Down syndrome. *Prenatal Diagnosis*, Mar;32(3):302-5, 2012.
97. Miller MC, Lambert-Messerlian GM, Eklund EE, Heath NL, Donahue JE, Stopa EG. Expression of inhibin/activin proteins and receptors in the human hypothalamus and basal forebrain. *J Neuroendocrinol*, Jun;24(6):962-72,2012.
98. Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. *Am J Obstet Gynecol* 206: (4):349, 2012.
99. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. *Am J Obstet Gynecol* Apr 206(4):351, 2012.
100. Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. *Genet Med*. 14(3):296-305, 2012.
101. Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma to identify Down syndrome, trisomy 18, and trisomy 13 in multiple gestations. *Prenatal Diagnosis*, May 14:1-5, 2012.
102. Lambert-Messerlian GM, Palomaki GE, Eklund EE, Kloza EM, Neveux LM, Phipps MG and Canick JA. Feasibility of using plasma rather than serum in first and second trimester multiple marker Down's syndrome screening. *J Med Screen*, 19(4):164-70, 2012.
103. Haddow JE, Craig WY, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, and D'Alton ME for the FaSTER Research Consortium* Impact of Adjusting for the Reciprocal Relationship between Maternal Weight and Free Thyroxine during Early Pregnancy. *Thyroid*, 23(2): 225-30, 2013.
104. Canick JA, Palomaki GE, Kloza E, Lambert-Messerlian GM, Haddow JE. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies, *Prenat Diagn* 33:667-74, 2013.
105. Owen WE, Lambert-Messerlian G, Delaney C, Christenson R, Plouffe B, Ludewig R, Woods A, Lei J-D, Thompson S, Roberts WL, Straseski JA. Multi-site evaluation of a monoclonal IMMULITE erythropoietin immunoassay. *Clin Biochem*, 47(3):216-9 Feb 2014.

106. Lambert-Messerlian G, Kloza EM, Williams J 3rd, Loucky J, O'Brien B, Wilkins-Haug L, Mahoney MJ, De Biasio P, Borrell A, Ehrich M, van den Boom D, Bombard AT, Deciu C, Palomaki GE. Maternal plasma DNA testing for aneuploidy in pregnancies achieved by assisted reproductive technologies. *Genet Med*. 16(5):419-22 May 2014.
107. Moore RG, Hill EK, Horan T, Yano N, Kim K, MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller MC, Lange TS, Singh RK. HE4 (WFDC2) gene overexpression promotes ovarian tumor growth. *Sci Rep*. 4:3574, Jan 2014.
108. Palomaki G, Lambert-Messerlian G. Down syndrome screening: Suitability of a WHO 5 standardized total hCG assay. *Clin Biochem*, 47(7-8):629-31, May 2014.
109. Haddow JE, Craig W, Neveux L, Haddow H, Palomaki G, Lambert-Messerlian G, Malone FD, D'Alton ME. Implications of High Free Thyroxine (FT4) Concentrations in Euthyroid Pregnancies: The FaSTER Trial. *J Clin Endocrinol Metab*, 99(6):2038-44. Jun 2014.
110. Bourjeily G, Butterfield K, Curran P, Lambert-Messerlian G. Obstructive sleep apnea is associated with alterations in markers of fetoplacental wellbeing. *J Matern Fetal Neonatal Med*. 14:1-5, May 2014.
111. Lertsburapa TK, Vargas D, Lambert-Messerlian G, Tantravahi U, Gundogan F, DeLaMonte S, Coyle MG, DePaepe ME: Lethal hypoplasia and developmental anomalies of the lungs in a newborn with intrauterine adrenal hemorrhage and cerebral infarcts: A proposed pulmonary disruption sequence. *Pediatr Dev Pathol*. 17(5):374-81, Sep-Oct 2014
112. BM O'Brien, EM Kloza, JV Halliday, GM Lambert-Messerlian, and GE Palomaki. Maternal plasma DNA testing: experience of women counseled at a prenatal diagnosis center. *Genetic Testing and Molecular Biomarkers*. 18:665-9, Oct 2014.
113. Lambert-Messerlian G, Eklund EE, Chien EK, Rosene-Montella K, Neveux LM, Haddow HRM, Palomaki GE. Use of first or second trimester serum markers, or both, to predict preeclampsia. *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health*. *Pregnancy Hypertens*. 4(4):271-8, Oct 2014
114. Bourjeily G, Curran P, Butterfield K, Maredia H, Carpenter M, Lambert-Messerlian G. Placenta-secreted circulating markers in pregnant women with obstructive sleep apnea. *J Perinat Med*. 43(1):81-7. Jan 2015
115. Scherzer R, Bacchetti P, Messerlian G, Goderre J, Maki PM, Seifer DB, Anastos K, Karim R, Greenblatt RM. Impact of CD4+ lymphocytes and HIV infection on anti-mullerian hormone levels in a large cohort of HIV-infected and -uninfected women. *American Journal of Reproductive Immunology*. 73(3):273-84, Mar 2015.
116. Palomaki G, Kloza E, Lambert-Messerlian G, van den Boom D, Ehrich M, Deciu C, Bombard A, Haddow JE. Circulating cell free (ccf) DNA testing: are some test failures informative? *Prenat Diagn*. 35(3):289-93 Mar 2015
117. EM Kloza, PK Haddow, JV Halliday, BM O'Brien, GM Lambert-Messerlian, GE Palomaki. Evaluation of patient education materials: the example of circulating cell free DNA testing for aneuploidy. *J Genetic Counseling*, 24(2):259-66. Apr 2015

118. Palomaki GE, Ashwood ER, Best RG, Lambert-Messerlian G, Knight GJ. Is maternal plasma DNA testing impacting serum-based screening for aneuploidy in the United States? *Genet Med.* 17:897-900 Apr 2015.
119. Haddow JE, Neveux LM, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME for the First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium. An Inverse Relationship between Weight and Free Thyroxine (FT4) during Early Gestation among Women Treated for Hypothyroidism. *Thyroid* 25:949-953, Aug 2015
120. Palomaki GE, Eklund EE, Neveux LM, Lambert Messerlian GM. Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: High detection with low rates of invasive procedures. *Prenat Diagn.* 35(8): 789-96, Aug 2015.
121. Lambert-Messerlian G, Steinhoff M, Kumar A, Eklund E, Moore R. Comparison of inhibin alpha subunit and anti-müllerian hormone immunoreactivity in granulosa cell and mucinous ovarian tumors. *Applied Immunohistochemistry & Molecular Morphology*, 25(1):71-77, Jan 2017
122. Ravishankar, S, Bourjeily G, Lambert-Messerlian G, He M, De Paepe ME, Gundogan, F. Evidence of placental hypoxia in maternal sleep disordered breathing. *Pediatr Dev Pathol*, 18:380-6, Sep-Oct 2015
123. Irani M, Seifer DB, Grazi RV, Julka N, Bhatt D, Kalgi B, Irani S, Tal O, Lambert-Messerlian G, Tal R. Vitamin D Supplementation Decreases TGF- β 1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial, *J Clin Endocrinol Metab*, 100:4307-14, Nov 2015.
124. Lokich E, Palisol M, Romano N, Miller MC, Robison K, Stuckey A, DiSilvestro P, Mathews C, Granai C, Lambert-Messerlian G, Moore R. Assessing the risk of malignancy algorithm for the conservative management of women with a pelvic mass. *Gynecol Oncol*, 139:248052, Nov 2015.
125. Lambert-Messerlian G, Palomaki GE. Prenatal serum screening markers may not require adjustment in former smokers. *Prenatal Diagnosis*, 35:1371-3, Dec 2015.
126. Lambert-Messerlian G, Plante B, Eklund E, Raker C and Moore RG. Levels of anti-Müllerian hormone (AMH) in serum during the normal menstrual cycle. *Fertility and Sterility*, 105: 208-13, Jan 2016.
127. Haddow JE, Craig WY, Neveux LM, Palomaki GE, Lambert-Messerlian G, Malone FD, D'Alton ME; First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium. Free Thyroxine During Early Pregnancy and Risk for Gestational Diabetes. *PLoS One* 11(2): e0149065 Feb 2016
128. Maredia H, Lambert-Messerlian GM, Palomaki GE, Viali S, Hawley NL, McGarvey ST. Cut-off levels for hyperandrogenemia among Samoan women: An improved methodology for deriving normative data in an obese population. *Clin Biochem.* Jul 49:782-6, 2016
129. Palomaki GE, Lambert-Messerlian G, Haddow JE. Serum Versus cfDNA Screening: Where Have All the Trisomies Gone? *American Journal of Obstetrics & Gynecology*. 215:583-7, Nov 2016.
130. Scherzer R, Greenblatt RM, Merhi ZO, Kassaye S, Lambert-Messerlian G, Maki PM, Anastos K, Karim R, Bacchetti P. Use of Anti-Müllerian hormone (AMH) to predict the menopausal transition in HIV-infected women. *American Journal of Obstetrics & Gynecology*, 216:46e1-11, Jan 2017.

131. G Lambert-Messerlian, E Eklund, L Neveux, G Palomaki. Measuring maternal serum screening markers for Down's syndrome in plasma collected for cell-free DNA testing. *Journal of Medical Screening* 24:113-9, Sept 2017.
132. Farina A, Eklund E, Bernabini D, Paladino A, Righetti F, Monti G, Lambert-Messerlian G. A first trimester biomarker panel for predicting the development of gestational diabetes. *Reproductive Sciences*, 24: 954-9 Jun 2017
133. Lee J, Eklund E, Lambert-Messerlian G, Butterfield K, Curran P, Bourjeily G. Serum progesterone levels in women with obstructive sleep apnea during pregnancy. *Journal of Women's Health (Larchmt)* 26:259-65. Mar 2017
134. Palomaki, GE, Kloza EM, O'Brien BM, Eklund, EE, Lambert-Messerlian G. The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical providers in the general population. *Genetics in Medicine*, 19: 778-86. Jul 2017
135. O'Brien BM, Halliday J, Lambert-Messerlian G, Eklund EE, Kloza EM, Palomaki GE. Nuchal translucency measurement in the era of prenatal screening for aneuploidy using cell free (cf) DNA. *Prenat Diagn*, 37:303-5. Mar 2017
136. Khan N, Lambert-Messerlian G, Monteiro JF, Hodosy J, Tóthová L, Celec P, Eklund, E, Curran P, Bourjeily G. Oxidative and carbonyl stress in pregnant women with obstructive sleep apnea. *Sleep and Breathing*, 22(1):233-240, Mar 2018
137. Moore RG, Plante B, Hartnett E, Mitchel J, Raker CA, Vitek W, Eklund E, Lambert-Messerlian G. Assessment of serum HE4 levels throughout the normal menstrual cycle. *Am J Obstet Gynecol*, 217: 53. e1-9. Jul 2017
138. Garg D, Grazi R, Lambert-Messerlian G, Merhi Z. Correlation between follicular fluid levels of sRAGE and vitamin D in women with PCOS. *Journal of Assisted Reproduction and Genetics*. 34(11):1507-1513. Nov 2017
139. Haddow JE, Lambert-Messerlian G, Eklund E, Neveux LM, Palomaki GE. Peripheral deiodinase activity: a potential explanation for the association between maternal weight and gestational hyperglycemia. *Obstetric Medicine*, 11(2):73-78, Jun 2018
140. Graves JS, Henry RG, Cree BAC, Lambert-Messerlian G, Greenblatt RM, Waubant E, Cedars MI, Zhu A, Bacchetti P, Hauser SL, Oksenberg JR. Ovarian aging is associated with gray matter volume and disability in women with MS. *Neurology*;90(3):e254-e26, Jan 2018.
141. Rehfeldt M, Eklund E, Struck J, Sparwasser A, O'Brien B, Palomaki G, Köhrle J, Bergmann A, Lambert-Messerlian G. Relaxin-2 connecting peptide (pro-RLX2) levels in second trimester serum samples to predict preeclampsia. *Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health*. 11:124-128, Jan 2018.
142. Maredia H, Hawley NL, Lambert-Messerlian G, Fidow U, Reupena MS, Naseri T, McGarvey ST. Reproductive health, obesity, and cardiometabolic risk factors among Samoan women. *American Journal of Human Biology*, 30(3): e23106, May 2018
143. Colón-Franco JM, Bossuyt PMM, Algeciras-Schimmich A, Bird C, Engstrom-Melnyk J, Fleisher M, Kattan M, Lambert-Messerlian G. Current and Emerging Multianalyte Assays with Algorithmic Analyses- Are Laboratories Ready for Clinical Adoption? *Clin Chem*. 64(6):885-891, Jun 2018

144. Myriam Salameh, Jennifer Lee, Glenn Palomaki, Elizabeth Eklund, Patrizia Curran, Jose Antonio Rojas Suarez, Geralyn Lambert-Messerlian, Ghada Bourjeily. Snoring and markers of fetal and placental wellbeing. *Clin Chim Acta*, 485:139-143, Oct 2018
145. Lambert-Messerlian G and Palomaki GE. Fewer women aged 35 and older choose serum screening for Down's syndrome: Impact and implications. *J Med Screen*. 26(2):59-66, Jun 2019
146. Ghada Bourjeily, Alison Chambers, Myriam Salameh, Margaret H Bublitz, Amanpreet Kaur, Alexandra Coppa, Patricia Risica, Geralyn Lambert-Messerlian. Anthropometric measures and prediction of maternal sleep disordered breathing. *J Clin Sleep Med*, 15(6):849-856. Jun 2019.
147. James E Haddow, Boyd E. Metzger, Geralyn Lambert-Messerlian, Elizabeth Eklund, Donald Coustan, Patrick Catalano, Glenn E Palomaki. Maternal BMI, Peripheral Deiodinase Activity, and Plasma Glucose: Relationships among a Subset of Caucasian Women in the HAPO Study. *J Clin Endocrinol Metab*, 1;104(7):2593-2600, Jul 2019.
148. Moore RG, Miller CM, Robison K, DiSilvestro PA, Eklund EE, Strongin R, Messerlian G. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance? *Gynecol Oncol*, 154(1):150-155, Jul 2019
149. Yelena Dondik, Kelly Pagidas, Eizabeth Eklund, Christina Ngo, Glenn E Palomaki, Geralyn Lambert-Messerlian. Levels of angiogenic markers in second trimester maternal serum from *in vitro* fertilization pregnancies with oocyte donation. *Fertility and Sterility*, 112(6):1112-1117, Dec 2019
150. Underhill L, Avalos N, Tucker R, Zhang Z, Messerlian G, Lechner B. Serum Decorin and Biglycan as Potential Biomarkers to Predict PPRM in Early Gestation. *Reprod Sciences*, 27(8):1620-1626, Aug 2020
151. Palomaki GE, Kalra B, Kumar T, Patel AS, Savjani G, Torchen LC, Dunaif A, Lambert-Messerlian GM, Kumar A. Adjusting anti-Müllerian hormone levels for age and body mass index improves detection of polycystic ovary syndrome. *Fertil Steril*, 113(4):876-884, Apr 2020.
152. Madison T Ortega, Lauren Carlson, John A. McGrath, MA, Tairmae Kangarloo, Judith Mary Adams, RN, DMU, Patrick Sluss, PhD, Geralyn Messerlian, PhD, and Natalie D Shaw, MSc MD. AMH is higher across the menstrual cycle in healthy early post-menarchal girls than in ovulatory women. *J Clinical Endo Metab*, 1;105(4), Apr 2020.
153. Jenna M. Mennella, Lori A. Underhill, Sophia Collis, Geralyn M. Lambert-Messerlian, Richard Tucker, Beatrice E. Lechner. Serum Decorin, Biglycan, and Extracellular Matrix Component Expression in Preterm Birth. *Reprod Sci*. 28(1):228-236. Jan 2021
154. B Harlow, Samuel W Golenbock, Lauren Wise, Geralyn Lambert-Messerlian, Elizabeth E Eklund. Association between a History of Depression and Anti-Müllerian Hormone among Late-Reproductive Aged Women, *Women's Midlife Health*, Sep 1;6:9; 2020
155. Huber WJ, Sauerbrun-Cutler M, Krueger PM, Lambert-Messerlian G, Sharma S. Human chorionic gonadotropin-mediated modulation of pregnancy compatible peripheral natural killer cells in frozen embryo transfer cycles. *Am J Reprod Immunol*, *Am J Reprod Immunol*. Jan;85(1): e13324, Jan 2021
156. Felicia C. Chow, Yifei Ma, Maura Manion, Adam Rupert, Geralyn Lambert-Messerlian, Cheryl Bushnell, Marcelle Cedars, Rebecca Scherzer, Irini Sereti, Farzaneh Sorond, Priscilla Hsue, Phyllis C.

Tien. Factors associated with worse cerebrovascular function in reproductive aging women with and at risk for HIV. *AIDS*, 2; 35(2):257-266, Feb 2021.

157. Alexandra Blackman, Jessica Mitchell, Racheal Turner, Rakesh Singh, KyuKwang Kim, Elizabeth Eklund, Steven Skates, Robert Bast, Geralyn Messerlian, M. Craig Miller and Richard G. Moore. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors. submitted, *Tumor Biol.* 43(1):355-365, Dec 2021.

158. Sanapo, L, Bublitz, M, Bai, A, Mehta, N, Messerlian, G, Catalano, P, Bourjeily, G. Association between Sleep Disordered Breathing in Early Pregnancy and Glucose Metabolism. *Sleep*, 11;45(4): Apr 2022.

159. David B. Seifer; Geralyn M. Lambert-Messerlian; Glenn E. Palomaki; Robert M. Silver; Corette Parker; Carol J. Rowland Hogue; Barbara J. Stoll; George R. Saade; Robert L. Goldenberg; Donald J Dudley; Radek Bukowski; Halit Pinar; Uma M. Reddy. Preeclampsia at Delivery Is Associated with Lower Serum Vitamin D and Higher Antiangiogenic Factors: A case control study. *Reprod Biol Endocrinol.* 20(1):8 Jan 2022

160. Whelan AR, Lambert-Messerlian GM, Kloza EM, Palomaki GE. First trimester screening for preeclampsia: estimated versus measured mean arterial pressure. *Ultrasound in Obstetrics and Gynecology*, doi: 10.1002/uog.24850. Online ahead of print. Jan 2022

161. Reid Shaw, Anna E. Lokshin, M. Craig Miller, Geralyn Messerlian-Lambert, Richard G. Moore. Stacking Machine Learning Algorithms for Biomarker-Based Preoperative Diagnosis of a Pelvic Mass. *Cancers*, 14: 1291, March 2022.

162. GE Palomaki, EE Eklund MS, EM Kloza, GM Lambert-Messerlian. Assessment of a simplified cell free (cf)DNA method for prenatal Down syndrome screening. *Clin Chem*, in press, July 2022.

163. Hardy EJ, Palomaki GE, Sung CJ, Lambert-Messerlian G. Surveillance of SARS-CoV-2 antibodies in early 2020 among Rhode Island pregnancies. *Annals of Clin & Lab Sci*, in press, July 2022

164. Samborski, A., Miller M.C., Blackman, A., MacLaughlan, S., Jackson, A., Lambert-Messerlian G., Rowswell-Turner, R., Moore R.G. HE4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancer. *Tumor Biology* 44: 205-213, Oct 2022.

PUBLICATIONS IN PROGRESS

Grace O'Brien, Geralyn Lambert-Messerlian, Nicola L. Hawley, Ulai T. Fidow, Take Naseri, Muagututi'a Sefuiva Reupena, Stephen T. McGarvey. Anti-Mullerian Hormone Reference Range for Reproductive Aged Samoan Women. *Clinical Biochem*, in preparation 2020

Bourjeily G, Lambert-Messerlian G. A longitudinal study of impulse oscillometry and respiratory mechanics in pregnancy: Implications for respiratory disorders. In preparation

Lauren A Wise, Tanran R. Wang, Amelia K. Wesselink, Ganesa Wegienka, Ruth G. Geller, Chad M. Coleman, Mary D. Willis, Erica E. Marsh, Antonia Calafat, Geralyn Messerlian-Lambert, Ellen M. Mikkelsen, Elizabeth E. Hatch. Perfluoroalkyl and Polyfluoroalkyl Substances and Anti-Müllerian Hormone Concentrations in Two Preconception Cohort Studies. *EHP*, Brief Report, 2022

Geralyn M Lambert-Messerlian, Jonathan P Bestwick, and Nicholas J Wald. Validation of a monoclonal unconjugated estriol antibody for use in prenatal maternal serum screening. JMS, 2022

Rebecca A. ABELMAN, Thuy Trang J. NGUYEN, Yifei MA, Peter BACCHETTI, Geralyn MESSERLIAN, Audrey L. FRENCH, Anjali SHARMA, Howard MINKOFF, Michael PLANKEY, Elizabeth TOPPER, Carl GRUNFELD, Phyllis C. TIEN. Body composition changes over the menopausal transition in women with and without HIV. Clinical Infectious Diseases, submitted 2022

OTHER PUBLICATIONS

1. Lambert GM. A short review: Exercise and the premenstrual syndrome. J Applied Sport Sci Res 2(1): 16-19, 1988.

2. Schneyer A, Lambert-Messerlian G, Sluss P, Isaacson K, and Crowley WF Jr. Do alpha inhibin proteins have a role in gonadal physiology? In: Frontiers in Endocrinology: Inhibin and Inhibin Related Proteins. Ed. HG Burger et al., Ares Serono Symposium, Serono Symposium Publications, Rome Italy, 1994.

3. Lambert-Messerlian GM, Canick JA and Palomaki GE. Maternal serum total activin A in pregnancies affected with fetal Down syndrome. J Med Screen, 3: 217, 1996 (letter).

4. Lambert-Messerlian G and Canick JA. Endocrine analytes in multiple marker screening. Clinics in Perinatology. J Strauss III and W Miller (eds.), W.B. Saunders Co., Philadelphia, PA, 25 (4), 963-981, 1998.

5. Lambert-Messerlian GM. Is inhibin a serum marker for ovarian cancer? Eur J Endocrinol, 142: 331-333, 2000 (Invited Commentary).

*6. Lambert-Messerlian G. Physiology and pathophysiology of inhibin A and activin A in human pregnancy. Cur Opin Endocrinol Diabetes, 7: 337-344, 2000 (Review).

7. Canick JA, Messerlian GM, Farina A. General principles of second trimester maternal serum screening for Down syndrome. In: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2002-2007

8. Canick JA, Messerlian GM, Farina A. Second trimester maternal serum screening for Down syndrome. UpToDate, Rose, BD (Ed), Wellesley, MA, 2002-2007.

9. Canick JA, Messerlian GM, Farina A. Pregnancy complications predicted by second trimester maternal serum screening. UpToDate, Rose, BD (Ed), Wellesley, MA, 2002-present.

10. Lambert-Messerlian G. Recent developments in inhibin and activin as ovarian tumor markers. Inhibitions (Inhibin and activin research newsletter), 5:2, 2002. (Invited contribution)

11. Messerlian GM, Canick JA. Recent advances in maternal serum screening for Down syndrome. Medicine and Health, Rhode Island, 85:362-5, 2002.

12. Lambert-Messerlian G. The value of inhibin B: predicting success in IVF. Family Building, Resolve: The National Infertility Organization, 2:12, 2002.

13. Lyell DJ, Lambert-Messerlian G, Giudice LC. Prenatal screening, epidemiology, diagnosis and management of preeclampsia. Clinics in Laboratory Medicine, J Canick and G Lambert-Messerlian (eds.), 23(2): 413-442, 2003

14. Florio P, Lambert-Messerlian G^{*}, Severi FM, Buonocore G, Canick JA, Petraglia F. Fetal neural tube defects: maternal serum and amniotic fluid activin A levels. *Prenat Diagn*, 24(7):574-5, 2004. (*co-first author, letter)
15. Lambert-Messerlian G, Halliday J, Williams J, Cain R, Msall M, Palomaki GE, Canick JA. Effect of folic acid supplementation on prevalence of neural tube defects in Rhode Island. *J Med Screen*, 11: 106-107, 2004. (letter)
16. Canick JA, Saller DN Jr., Lambert-Messerlian GM. Prenatal screening for Down syndrome: current and future methods. *Clinics in Laboratory Medicine*, J Canick and G Lambert-Messerlian (eds.), 23(2): 395-412, 2003.
17. Lambert-Messerlian GM, Canick JA. Clinical Application of Inhibin A Measurement: Prenatal Serum Screening for Down Syndrome. *Seminars in Reproductive Medicine: Issue on Inhibins*, GM Lambert-Messerlian and VD Castracane (eds.), 22(3):235-242, 2004.
18. Lambert-Messerlian GM, Keren D, Raptis CS, Byberg K, Canick JA. Apparently low maternal serum inhibin A levels in second trimester screening. *Prenat Diagn*, 25(10):967-968, Oct 2005. (Letter)
19. Barss VA, Canick JA, Lambert-Messerlian GM. Overview of prenatal screening and diagnosis of Down syndrome. *UpToDate*, Barss VA (Ed), Wellesley, MA, 2005- 2012.
20. Lambert-Messerlian G, Bandera C, Eklund E, Neuhauser A, Canick J. Very high inhibin A level attributed to heterophilic antibody interference. *Clin Chem*, Apr; 53 (4):800-1, 2007. (Letter)
21. Messerlian GM, Palomaki GE. Laboratory issues related to maternal serum screening for Down Syndrome. *UpToDate*, Barss, V (Ed), Wellesley, MA, 2008-present.
22. Messerlian GM, Farina A, Palomaki GE. First trimester combined and integrated tests for screening for Down syndrome and trisomy 18. *UpToDate*, Barss, V (Ed), Wellesley, MA, 2008-present.
23. Canick J, Messerlian GM, Halliday, J, Second trimester screening for Down syndrome *UpToDate*, Barss, V (Ed), Wellesley, MA, 2008-2014.
24. Halliday, J, Messerlian GM, Palomaki GE. Patient information: Should I have a screening test for Down syndrome during pregnancy? *UpToDate*, Barss, V (Ed), Wellesley, MA, 2008-present.
25. Messerlian GM Ped iPath Puzzlers: Contributor (Weekly quiz in the field of pediatric/perinatal pathology, peer reviewed within the Department, and distributed electronically to residents, fellows and faculty of the Departments of Pathology, Pediatrics and Obstetrics/Gynecology). PPP 10-7: Prenatal screening test – I, 2010 and PPP 10-18: Prenatal screening test – II, 2010: PPP 12-01: Neural tube defects.
26. Messerlian GM, Palomaki GE. Down syndrome: prenatal screening overview. *UpToDate*, Barss, V (Ed), Wellesley, MA, 2013-present.
27. Palomaki GE, Messerlian G, Halliday J. Prenatal screening for common aneuploidies using cell free DNA. *UpToDate*, Barss, V (Ed), Wellesley, MA, 2015-present.
28. Lambert-Messerlian G. Noninvasive Prenatal Screening: Going Beyond High-Risk Pregnancies. *Ask the Expert, Clinical Laboratory News*, Dec 2019.

29. Lambert-Messerlian G. Pregnancy and its Disorders. Area 9 Rhapsode Curator. On-line learning Posted, 2019.

30. Johnson L, Genzen J, Algeciras A, Bornhorst J, Lambert-Messerlian G. PAPP-A Results Cannot Be Used to Accurately Estimate Gestational Age. J Applied Lab Med, June 2022 (letter).

BOOKS AND BOOK CHAPTERS

1. Clinics in Laboratory Medicine, Issue on Prenatal Testing. J Canick and G Lambert-Messerlian (eds), WB Saunders, Philadelphia, PA, 23(2), 2003.

2. Seminars in Reproductive Medicine, Issue on Inhibins, GM Lambert-Messerlian and VD Castracane (eds.). Thieme Publishing, New York, 22(3), 2004.

3. Ashwood ER, Grenache D and Lambert-Messerlian GM. Pregnancy and its disorders. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 5th ed, Elsevier Saunders, St Louis MO, 2012

4. Grenache D and Lambert-Messerlian G. Pregnancy and prenatal testing. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics, 7th ed., Elsevier Saunders, St. Louis MO, 2013.

5. Lambert-Messerlian G and Rey R. AMH in diagnosis and treatment of gonadal tumors. Anti-müllerian Hormone: Biology, Role in Ovarian Function, and Clinical Significance. Nova Publishers, 2016

6. LaGrave D, Devers Winters P and Lambert-Messerlian G. Prenatal screening technologies and test issues. Practical Genetic Counseling for the Laboratory, Oxford Press, 2017

ABSTRACTS

1. Lambert GM, Erskine MS and Baum MJ. Naloxone augments LH pulse frequency in gonadectomized male and female ferrets before, but not after, estradiol replacement. Society for Neuroscience, St Louis MO, October 1990.

2. Lambert GM, Rubin BS and Baum MJ. Hypothalamic release of LHRH is reduced after mating or gonadectomy in breeding female, but not in male, ferrets. Society for Neuroscience, New Orleans LA, November 1991.

3. Lambert GM, Rubin BS and Baum MJ. Sex difference in the effect of mating on *c-fos* immunoreactivity in LHRH neurons of the ferret. Society for Neuroscience, Anaheim CA, October 1992.

4. Lambert GM and Schneyer AL. Post-translational processing of alpha inhibin in human follicles. 75th Annual Meeting of the Endocrine Society. Las Vegas NV, June 1993.

5. Good TEM, Ireland JLH, Weber PSD, McConnell DS, Padmanabhan V, Schneyer AL, Lambert-Messerlian G, Groome N and Ireland JJ. Isolation and immunological characterization of different inhibin forms. 27th Annual Meeting of the Society for Reproduction, Ann Arbor MI, July 1994.

6. Hall JE, Lambert-Messerlian GM, Christian S, Martin KA, Khoury R, Sluss PM, Groome NP, Crowley WF Jr and Schneyer AL. Dynamics of dimeric inhibin and follicle-stimulating hormone (FSH) secretion during the luteal-follicular transition. 76th Annual Meeting of the Endocrine Society, Anaheim CA, June 1994.

7. Schneyer AL, Lambert-Messerlian GM, Crowley WF Jr, Hall JE, Martin KA, Sluss PM, Taylor AE and Groome NP. Circulating dimeric inhibin levels in men and women using a novel two-site immunoassay. 76th Annual Meeting of the Endocrine Society, Anaheim CA, June 1994 (Oral presentation).
8. Lambert-Messerlian GM, Crowley WF Jr and Schneyer AL. Extragonadal alpha inhibin precursor proteins in human male serum. 76th Annual Meeting of the Endocrine Society, Anaheim CA, June 1994.
9. Canick JA, Lambert-Messerlian GM, Palomaki GE, Schneyer AL, Tumber MB, Knight GJ and Haddow JE. Maternal serum dimeric inhibin is elevated in Down syndrome pregnancy. American Society of Human Genetics. 1994 (Oral presentation).
10. Seifer DB, Canick JA, Frishman GN, Lambert-Messerlian GM and Schneyer AL. Serum total and dimeric inhibin levels are lower in ectopic than in normal spontaneously conceived intrauterine pregnancies. Society for Gynecologic Investigation, Chicago, 1995.
11. Seifer DB, Gardiner AC, Wheeler CA, Lambert-Messerlian GM and Schneyer AL. Differential secretion of inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. Society for Gynecologic Investigation, Chicago, 1995.
12. Schneyer AL, Hall HA, Lambert-Messerlian GM and Crowley WF Jr. Immunological and biochemical differences between hFF and serum derived follistatin (Fs). 77th Annual Meeting of the Endocrine Society, Washington DC, 1995.
13. Canick JA, Kellner LH, Saller DN, Palomaki GE, Tumber MB, Messerlian GM, Walker RP and Osathanondh. A second level evaluation of maternal urinary gonadotropin peptide as a marker for second trimester Down syndrome screening. 3rd Joint Clinical Genetics Meeting, San Antonio TX 1996.
14. Hall JE, Martin KA, Taylor AE, Khoury R, Sluss P, Lambert-Messerlian G, Schneyer AL and Crowley WF Jr. Reciprocal changes in inhibin B and inhibin A during the normal menstrual cycle. 78th Annual Meeting of the Endocrine Society, San Francisco CA, June 1996.
15. Lambert-Messerlian G, Taylor A, Isaacson K, Leykin L, Toth T, Hall HA and Schneyer A. Intrafollicular inhibin concentrations differ between women with and without polycystic ovarian syndrome. 78th Annual Meeting of the Endocrine Society, San Francisco CA, June 1996.
16. Lambert-Messerlian G, Steinhoff M, Zheng W, Seifer D and Schneyer A. Secretion of dimeric inhibin B and alpha inhibin subunits in women with epithelial ovarian cancer. 78th Annual Meeting of the Endocrine Society, San Francisco, CA, June 1996.
17. Kellner LH, Canick JA, Palomaki GE, Saller DN, Lambert-Messerlian GM, Nuer M, Osathanondh R and Bombard AT. Urinary markers: a new approach to screening for Down syndrome in the second trimester. American Society for Human Genetics, October 1996.
18. Seifer DB, Lambert-Messerlian GM, Berk C, Gardiner AC, Hogan JW and Blazer AS. Day 3 serum dimeric inhibin B is predictive of outcome in ART. American Society for Reproductive Medicine, Boston, MA, November 1996.
19. Lambert-Messerlian GM and Canick JA. Levels of total activin A in second trimester maternal serum from normal pregnancies and those affected with fetal Down syndrome. International Conference on Inhibin, Activin, Follistatin. Recent Advances and Future Views. Tokushima Japan, November 1996.

20. Lambert-Messerlian G, Taylor A, Isaacson K, Leykin L, Toth T, Hall HA and Schneyer A. Intrafollicular activin concentrations in women with and without polycystic ovarian syndrome. 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, June 1997.
21. Welt C, Lambert-Messerlian G and Schneyer A. Serum activin levels in patients with epithelial ovarian cancer. 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, June 1997.
22. Seifer DB, Phipps M, Lambert-Messerlian G, Palomaki G, Peipert J and Canick JA. Combination of single serum progesterone and inhibin-A differentiates viable from non-viable spontaneously conceived pregnancies in early first trimester. American Society for Reproductive Medicine, Cincinnati, Ohio, Fertil Steril 68: S13, 1997 (Oral presentation).
23. Lambert-Messerlian GM, Tumber MB, Saller DN Jr., French CA, Peterson CJ and Canick JA. Second trimester levels of maternal serum inhibin A in fetal trisomy 18 and in Turner syndrome with and without hydrops. American Society Human Genetics, Baltimore, Maryland, October 1997.
24. Silver H, Messerlian G, Star J, Hogan J and Canick J. Maternal serum inhibin A levels in preeclampsia, nonproteinuric pregnancy-induced hypertension and normotensive pregnancy. Society of Perinatal Obstetricians, Miami Beach, FL, February 1998.
25. Lambert-Messerlian G, Depasquale S, Gajewski W, Maybruck W and Steinhoff M. The patterns of secretion of inhibin pro-alpha C and activin A in recurrent epithelial ovarian carcinoma. New England Association of Gynecologic Oncologists, New Hampshire, June 1998.
26. Blazar AS, Knight G, Messerlian G, Hogan J, Pierce D and Keefe D. Antiphospholipid antibodies impact implantation rate during in vitro fertilization (IVF). American Society for Reproductive Medicine, San Francisco, October 1998.
27. Lambert-Messerlian GM, Silver H, Petraglia F, Luisi S, Plaino L, Yamamoto H and Canick JA. Second trimester maternal serum levels of inhibin A and human chorionic gonadotropin as markers for prediction of preeclampsia. American Society Human Genetics, Denver, Colorado, October 1998.
28. Rausch DN, Lambert-Messerlian GM and Canick JA. Effects of results of prenatal maternal serum screening on participation in screening in a subsequent pregnancy. American Society Human Genetics, Denver, Colorado, October 1998.
29. Plevyak M, Lambert-Messerlian G, Maybruck W and Silver H. Total serum activin A levels in term and preterm labor. Society for Maternal-Fetal Medicine, San Francisco, California, January 1999.
30. Silver H, Lambert-Messerlian G, Yamamoto H and Canick J. Maternal serum leptin levels in preeclampsia, nonproteinuric gestational hypertension and normotensive pregnancy. Society for Maternal-Fetal Medicine, San Francisco, California, January 1999.
31. Silver HM, Lambert-Messerlian GM and Canick JA. Mechanism of increased maternal serum total activin A and inhibin A in preeclampsia. Society for Gynecologic Investigation, Atlanta, Georgia, March 1999.
32. Plevyak M, Lambert-Messerlian GM, Maybruck W and Silver H. The effect of labor on inhibin A levels. Society for Gynecologic Investigation, Atlanta, Georgia, March 1999.

33. Star J, Silver H, Messerlian G, Tillinghast J and Canick J. Maternal serum inhibin A levels in term diabetic patients with and without hypertensive disease. Society for Gynecologic Investigation, Atlanta, Georgia, March 1999.
34. Dzik A, Izzo VM, Soares JB, Pinotti JA, Messerlian GM and Seifer DB. Prediction of response to controlled ovarian hyperstimulation: A pilot study of delta 24 hours/ inhibin B gonadotropin challenge test. IVF World Congress, Sydney, Australia, May 1999.
35. DePasquale S, Lambert-Messerlian G, Maybruck W, Dukic V, Steinhoff M and Gajewski W. Preoperative evaluation of serum activin A levels in patients with ovarian pathology: benign versus malignant disease. New England Association of Gynecologic Oncologists, Providence, RI, June 1999.
36. Veloudis GM, Seifer DB, Lambert-Messerlian GM, Buyalos. Ovarian volume by magnetic resonance imaging predicts ovarian reserve in premenopausal and postmenopausal women. American Society for Reproductive Medicine, Toronto, Ontario, Canada, September 1999.
37. Malee MP, Messerlian G, Tucker R and Vohr B. Leptin in the offspring of diabetic gestations: evidence of programming for obesity? Society for Maternal Fetal Medicine, Miami Beach, FL, January 2000.
38. Silver H, Messerlian G and Canick J. Maternal serum activin A and inhibin A levels for prediction of preeclampsia in patients evaluated for "R/O preeclampsia". Society for Maternal-Fetal Medicine, Miami Beach, FL, January 2000.
39. DePasquale S, Lambert-Messerlian G, Steinhoff M, Quddus M, Gajewski W and Tantravahi U. Molecular analysis of activin A and inhibin A subunit gene loci in epithelial ovarian cancer (EOC). SmithKline Beecham National Gynecologic Oncology Fellows Research Meeting, San Diego, CA, February 2000.
40. Lambert-Messerlian GM, Verma A, Heber W and Wheeler C. Peritoneal fluid inhibin A and B levels in women with endometriosis. 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 2000.
41. Levy DP, Navarro JM, Liu H-C, Lambert-Messerlian G, Schattman GL and Rosenwaks Z. Day 3 inhibin-B measurements and immediate IVF outcome following a short GnRH agonist stimulation protocol. 82nd Annual Meeting of the Endocrine Society, Toronto, Canada, June 2000.
42. Wheeler CA, Heber W and Lambert-Messerlian GM. Inhibin A levels in very early *in vitro* fertilization (IVF) pregnancies are predictive of pregnancy outcome. American Society for Reproductive Medicine, San Diego, Fertil Steril 3: S141-2, 2000.
43. Knight GJ, Palomaki GE, Neveux LM, Haddow JH, Lambert-Messerlian GM and Canick JA. Clinical validation of a new dimeric inhibin-A assay suitable for second trimester Down syndrome screening. Inhibins, Activins and Follistatins (Satellite meeting of 11th International Congress of Endocrinology), Monash Medical Centre, Melbourne, Australia, October 2000.
44. Simon P, Palomaki G, Williams J, Cain R, Messerlian G, Msall M, Halliday J and Viner-Brown S. Rhode Island birth defects surveillance: a pilot study of open neural tube defects in Rhode Island. National Birth Defects Prevention Network 4th Annual Meeting, San Antonio, TX, January 2001.
45. Lambert-Messerlian G, Florio P, Petraglia F, Severi F and Canick J. Activin A levels in pregnancies affected with neural tube defects. 51st Annual Meeting of the American Society of Human Genetics, San Diego, CA, October 2001.

46. Lee T, LeShane ES, Messerlian GM, Canick JA, Carpenter MW, Heber W and Bianchi DW. Fetal Down syndrome is associated with increased cell-free fetal DNA levels in archived maternal serum samples. Society for Maternal Fetal Medicine, New Orleans, LA, January 2002. (Oral presentation)
47. Schneyer A, Fox J, Welt C, Messerlian G, Taylor A. Inhibin A and B biosynthesis is deficient in arrested PCOS follicles relative to size-matched normal follicles. Ovarian Workshop, Baltimore, MD, July 2002.
48. Lambert-Messerlian G, Clark B, Star J, Canick J. Effect of screening covariates on second trimester maternal serum inhibin A levels. Society for Maternal Fetal Medicine, San Francisco, CA, February 2003.
49. Pinar H, Lambert-Messerlian G, Carr S, Canick J. Complete hydatidiform mole coexisting with a live fetus. Northeast Pediatric Pathology Club, Women and Infants Hospital, Providence, RI, April 12, 2003 and Society for Perinatal Pathology, Cincinnati, October 2003.
50. Canick JA, Wald NJ, Malone FD, Porter TF, Nyberg DA, Comstock CH, Saade G, Eddleman K, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Sullivan L, Lambert-Messerlian G, Rudnicka A, Hackshaw A, D'Alton ME. Gestational age-based performance of Down syndrome screening markers: results from the faster trial. Society for Maternal Fetal Medicine, New Orleans, LA, Am J Obstet Gynecol, 189: S116, 2003.
51. D'Alton ME, Malone FD, Lambert-Messerlian G, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Tripp T, Canick JA. Maintaining quality assurance for nuchal translucency sonography in a prospective multicenter study: results from the Faster trial. Am J Obstet Gynecol 189: S79, 2003.
52. Malone FD, Wald NJ, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Dukes KA, Bianchi DW, Rudnicka A, Hackshaw A, Lambert-Messerlian G, D'Alton ME. First and second trimester evaluation of risk (FASTER) trial: principal results of the NICHD multicenter Down syndrome screening study. Society for Maternal Fetal Medicine, New Orleans, LA, Am J Obstet Gynecol 189: S56, 2003
53. Malone FD, Wald NJ, Canick JA, Ball RH, Nyberg DA, Comstock CH, Saade G, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Sullivan L, Rudnicka A, Hackshaw A, Lambert-Messerlian G, D'Alton ME. Use of overall population, center-specific, and sonographer-specific nuchal translucency medians in Down syndrome screening: which is best? (Results from the FASTER trial). Society for Maternal Fetal Medicine, New Orleans, LA, Am J Obstet Gynecol, 189: S232, 2003.
54. Lambert-Messerlian GM, Palomaki GE, Knight GJ, Neveux LM, Canick JA, Haddow JE. Dimeric inhibin-A as a marker for Down Syndrome in the first trimester. Annual Meeting of the American College of Medical Genetics, Orlando, FL, March 4-7, 2004.
55. Lambert-Messerlian G, Canick J, Malone F, Porter F, Nyberg D, Comstock C, Saade G, Berkowitz R, Gross S, Dugoff L, Craigo S, Timor I, Carr S, Wolfe H, D'Alton M. First trimester levels of maternal serum hCG and inhibin A in pregnancies affected by fetal trisomy 18: A FASTER Trial study. Annual Meeting of the American College of Medical Genetics, Orlando, FL, March 4-7, 2004.
56. Roberson J, Diment S, Miller A, Lambert-Messerlian G, Canick J. Maternal serum integrated screening in clinical practice. Annual Meeting of the American College of Medical Genetics, Orlando, FL, March 4-7, 2004. (Oral presentation)

57. Messerlian G, Meiri H, Gonen R, Bindra R, Nicolaides K, Canick J. Placental protein 13 (PP-13) as a serum marker for early preeclampsia and IUGR. Placental Association of the Americas (PAA) Conference, Asilomar, CA September 26-29, 2004.
58. Pinar H, Lambert-Messerlian G, Eklund E, Schneyer A. Follistatin related protein (FSRP) expression is a marker of injury in growth impaired term placentas. Annual Perinatal Symposium of the Society for Perinatal Pathology, Little Rock, AK, October 2004.
59. Malone F, Lambert-Messerlian G, Canick J, Ball R, Nyberg D, Comstock C, Saade G, Berkowitz R, Gross S, Dugoff L, Craigo S, Timor I, Carr S, Wolfe H, Tripp T, Bianch D, D'Alton M. First and second trimester evaluation of risk (FASTER) trial: Detection of aneuploidies other than Down syndrome. Society for Maternal Fetal Medicine, Reno, NV, Am J Obstet Gynecol 191: S45, 2004.
60. D'Alton M, Luthy D, Malone F, Canick J, Gravett M, Lambert-Messerlian G, Tomlinson M, Rosenfeld R, Nagalla S. Detection of Down syndrome by proteomic profiling of maternal serum. Society for Maternal Fetal Medicine, Reno, NV, Am J Obstet Gynecol 191: S2, 2004.
61. Takoudes T, Weitzen S, Messerlian G, Malee M. Do steroids affect maternal or fetal thrombopoietin in preterm preeclampsia? Society for Maternal Fetal Medicine, Reno, NV, Feb 2005.
62. Lambert-Messerlian G, Dugoff L, Vidaver J, Canick J, Malone F, D'Alton M on behalf of the FASTER trial consortium. First and second trimester Down syndrome screening markers in pregnancies achieved through assisted reproductive technologies (ART): A FASTER trial study. Society for Maternal Fetal Medicine, Reno, NV, Am J Obstet Gynecol 191: S48, 2005.
63. Plante BJ, Phipps MG, Blume JD, Lambert-Messerlian G, Shackelton R, Pollock L. A multiple marker strategy to differentiate viable from non-viable pregnancies. Society for Gynecologic Investigation, Los Angeles, CA, Fertil Steril 84: S154, 2005.
64. Hartlage SA, Lambert-Messerlian G. Inhibin B as a potential biomarker of symptoms of premenstrual dysphoric disorder (PMDD). 63rd Annual Scientific Conference of the American Psychosomatic Society, Vancouver, British Columbia, Canada, March 2005.
65. Urato A, Peter I, Messerlian G, Canick J, Pulkkinen A, Knight G, Jeong YJ, Craigo S, Bianchi D. Circulating total cell-free DNA levels are increased in pregnant women who smoke. Society for Maternal Fetal Medicine, Miami Beach, FL, February 2006.
66. Cleary-Goldman J, Malone FD, Messerlian G, Sullivan L, Canick J, Ball R, Nyberg D, Gross S, D'Alton M. Subclinical hypothyroidism and pregnancy outcomes: Results from the FASTER trial. Society for Maternal Fetal Medicine, Miami Beach, FL, February 2006.
67. Hartlage SA, Soltes B, Lambert-Messerlian G. Inhibin B as a potential biological marker of premenstrual syndrome. 34th Annual Meeting of the North American Society for Psychosocial Obstetrics and Gynecology, Portland OR, Feb 8-10, 2007. (Oral presentation)
68. Blazar AS, Lambert-Messerlian G, Hackett R, Dondik, Y. Antimullerian hormone levels forecast performance in IVF cycles when obtained immediately prior to beginning FSH stimulation. 63rd Annual Meeting of the American Society for Reproductive Medicine, Washington, DC, Fertil Steril 88: S119, 2007.
69. Miller M, Eklund E, Stopa E, Donahue J, Lambert-Messerlian, G Expression of Inhibin/ Activin Family of Proteins in Human Brain. Annual Meeting of the Endocrine Society, San Francisco, June 2008.

70. Myers G, Lambert-Messerlian G, and Sigman M. Inhibin B reference data for fertile and infertile men in Northeast United States. Annual Meeting of the American Society for Reproductive Medicine, San Francisco, Fertil Steril 90: S311-312, 2008.
71. Friedman AM, Lambert-Messerlian G, Hayes M, Palomaki GE, Chien EK, Rosene-Montella K, Canick JA. Second trimester serum markers in women subsequently developing pre-eclampsia. Annual Meeting of the American Society for Hypertension, New Orleans, May 2008.
72. Vora NL, Johnson KL, Tighouart H, Peter I, Urato AC, Canick JA, Lambert-Messerlian G and Bianchi DW. Relationships between Cell Free DNA and Maternal Serum Marker Levels in the First and Second Trimesters of Pregnancy. Annual Scientific Meeting of the Society for Gynecologic Investigation, Glasgow, Scotland, March 17-21, 2009
73. Blazar AS, Krotz SP, Messerlian G, Hackett R, Robins JC. Antimüllerian hormone (AMH) levels at the onset of IVF predict outcome better than patient age or prior FSH levels. Annual Meeting of the American Society for Reproductive Medicine, Atlanta GA, Oct 2009. (Oral presentation)
74. Blazar AS, Krotz SP, Messerlian G, Robins JC. Antimüllerian hormone (AMH) levels decline during IVF cycles. Annual Meeting of the American Society for Reproductive Medicine, Atlanta GA, Oct 2009.
75. Johnson KL, Koide K, Jarrah Z, Peter I, Lambert-Messerlian G and Bianchi DW. Cell-free fetal DNA trafficking increases in pregnant women who conceive by *in vitro* fertilization using egg donors. Annual Meeting of the American Society of Human Genetics, Honolulu, Hawaii, October 2009.
76. Sprawka N, Messerlian G, Palomaki G, Canick J. The effect of oral hypoglycemic agents on maternal serum alpha-fetoprotein levels. Annual Meeting of the Society for Maternal Fetal Medicine, Chicago IL Feb 2010
77. Sprawka N, Messerlian G, Palomaki G, Canick J. The effect of oral hypoglycemic agents on maternal serum alpha-fetoprotein levels. International Society for Prenatal Diagnosis, Amsterdam, July 2010 (Oral presentation).
78. Lambert-Messerlian G, Eklund E, Neveux L, Canick J, Schneyer A. Follistatin related gene protein levels in second trimester pregnancy serum to predict the development of preeclampsia. Annual Meeting of the American Association of Clinical Chemistry, Anaheim CA, July 2010
79. Nelson HH, Almquist LM, LaRocca JL, Plaza SL, Lambert-Messerlian G, Sugarbaker DJ, Bueno R, Godleski JJ, Marsit CJ, Christensen BC, Kelsey KT. Serum SMRP (soluble mesothelin-related peptide) is determined by tumor *MSLN* methylation status in Malignant Pleural Mesothelioma: implications for screening studies. 10th International Conference of the International Mesothelioma Interest Group, Kyoto Japan, Aug 31 –Sep 3, 2010
80. Lindsay M. Almquist, Karl T. Kelsey, Jessica L. LaRocca, Silvia L. Plaza, Geralyn Lambert-Messerlian, David J. Sugarbaker, Raphael Bueno, E. Andres Houseman, John J. Godleski, Carmen J. Marsit, Brock C. Christensen, Heather H. Nelson- Low serum SMRP (soluble mesothelin-related peptide) identifies patients with extended survival for Malignant Pleural Mesothelioma 10th International Conference of the International Mesothelioma Interest Group, Kyoto Japan, Aug 31 –Sep 3, 2010
81. Cooper AR, Lambert-Messerlian G, French A, White A, Odem RR, Moley KH and Ratts VS. Antral Follicle Counts (AFC) and Anti-Müllerian Hormone (AMH) Measures In Prepubertal and Pubertal Girls As Compared To Reproductive Aged Females. Society for Gynecologic Investigation, Miami FL, March 2011.

82. McGarvey ST, Roberts MB, Urlacher S, Ah-Ching J, Viali S, Urbanek M, Lambert-Messerlian G. Assessment of menstrual cycle function and reproductive endocrine status in Samoan women. Annual Meeting of the Human Biology Association, Minneapolis MN, April 2011.
83. Merhi Z, Buyuk E, Israel D, Lambert-Messerlian GM, Eklund EE, Chua Jr S, Jindal S. Follicular Fluid Leptin/Adiponectin Ratio and Age Negatively Correlate with Anti-Mullerian Hormone Gene Expression in Human Luteinized Granulosa Cells. Annual Meeting of the Endocrine Society, Boston MA, June 2011
84. Kipp, J, Lambert-Messerlian G, Rodriguez G, Eklund E, Gundogan F. Regulation of alpha inhibin expression in placental tissue from pregnancies affected by fetal Down syndrome. Annual Meeting of the Endocrine Society, Boston MA, June 2011
85. Roberts WL, Lambert-Messerlian G, Delaney C, Plouffe B, Ludewig R, Woods A, Lei J, Thompson S. Performance Evaluation of a New IMMULITE® Erythropoietin Assay. Annual Meeting of the American Association of Clinical Chemists, Atlanta GA, July 2011.
86. GE Palomaki, C Deciu, EM Kloza, G Lambert-Messerlian, JE. Haddow, LM Neveux, M Ehrich, D van den Boom, AT Bombard, WW Grody, St Nelson, JA Canick. Sequencing of circulating cell free DNA (ccfDNA) in maternal plasma to detect Down syndrome, trisomy18 and trisomy 13: An international clinical validation study. Annual Meeting of the American College of Medical Genetics, Charlotte, NC, March 2012. (Oral)
87. E Kloza, G Palomaki, G Lambert-Messerlian, B O'Brien, J Halliday, J Canick. Prenatal identification of aneuploidy using sequenced circulating cell-free DNA (ccfDNA): Physician education and genetic counseling considerations. Annual Meeting of the American College of Medical Genetics, Charlotte, NC, March 2012.
88. Bourjeily G, Curran P, Lambert-Messerlian G. First and second trimester serum markers in pregnant women with sleep disordered breathing. SLEEP 2012, 26th Annual Meeting of the Associated Professional Sleep Societies, LLC. Boston MA, June 2012.
89. He M, Lambert-Messerlian G, Martin S, Curran P, Bourjeily G. Placental findings in obstructive sleep apnea. International Federation of Placenta Associations Annual Meeting, Japan, Sept 18-21, 2012
90. He M, Curran P, Martin S, Lambert-Messerlian G, Bourjeily G. Placental findings in pregnancy with maternal obesity. International Federation of Placenta Associations Annual Meeting, Japan, Sept 18-21, 2012
91. Richard G. Moore, MD, M. Craig Miller, Timothy Horan, Rakesh Singh, PhD, Nada Kavar, MD, Elizabeth Eklund, Geraldyn Messerlian, PhD, Douglas Hawkins, PhD, Carolyn McCourt, MD, C.O. Granai, MD. A novel marker for the management of women diagnosed with endometrial adenocarcinoma of the uterus. Annual Meeting of the Society for Gynecologic Oncology, Los Angeles, CA, March 2013.
92. Hill E, Singh RK, Horan TC, Yano N, Chu S, Mao Q, Kim K, Lange T, Lambert-Messerlian G, Moore RG. The oncogenic role of human epididymis protein (HE4): promotion of tumorigenesis, cell survival and cisplatin resistance in ovarian cancer in an *in vivo* mouse model. Annual Meeting of the Society for Gynecologic Oncology, Los Angeles, CA, March 2013.
93. O'Brien B, Halliday J, Palomaki GE, Kloza E, Lambert-Messerlian G, Canick JA. Maternal Plasma DNA Testing for Aneuploidy: Early Experience of a Prenatal Diagnosis Center" American College of Medical Genetics Annual Clinical Genetics Meeting, Phoenix AZ, March 2013

94. Scherzer R, Bacchetti P, Messerlian G, Goderre J, Maki PM, Seifer D, Ameli N, Anastos K, Karim R, Greenblatt R. CD4-Lymphocytes and Anti-Müllerian Hormone Levels in a Cohort of HIV-infected and – uninfected Women. Society of General Internal Medicine Annual Meeting, Denver CO, April 24-27, 2013.
95. Maredia H, Curran P, Lambert-Messerlian G, Butterfield K, Bourjeily G. Serum Markers of Angiogenesis in Pregnant Women with Obstructive Sleep Apnea. Annual Meeting of the Associated Professional Sleep Societies, Baltimore MD, June 2013.
96. J. Fung, G. Messerlian, P. Curran, K. Butterfield, S. Martin, G. Bourjeily. Obstructive sleep apnea is associated with alterations in markers of fetoplacental wellbeing. European Respiratory Society Meeting, Barcelona, Spain, Sept. 2013
97. H. Maredia, G. Messerlian, P. Curran, K. Butterfield, G. Bourjeily. Progesterone may play a protective role in the pathogenesis of SDB in pregnancy. European Respiratory Society Meeting, Barcelona, Spain, Sept. 2013
98. Maredia H, Lambert-Messerlian G, McGarvey S. Toward a better understanding of obesity-influenced menstrual cycle irregularity: the Samoan case. Annual Meeting of the Androgen Excess and PCOS Society, Newport, RI, Oct 2013 (Oral presentation)
99. A. Kumar, B. Kalra, A. S. Patel, G. Savjani, E. Eklund, G. Lambert-Messerlian. Pre-analytical assessment of AMH stability in human serum using a well characterized pro-mature immunoassay. Annual Meeting of the European Society of Human Reproduction and Embryology. Germany, June 2014.
100. A. Kumar, B. Kalra, A. S. Patel, G. Savjani, E. Eklund, G. Lambert-Messerlian. Pre-analytical assessment of AMH stability in human serum using a well characterized pro-mature immunoassay. Annual Meeting of the American Association of Clinical Chemistry. Chicago IL, July 2014.
101. Christensen, BC, Nelson, HH, Williams, LA, Chen, P, Lambert-Messerlian, GM, Sugarbaker, DJ, Bueno, R, Godleski, JJ, Kelsey, KT. Integrative analysis of SMRP levels, mesothelin miRNA binding site SNPs and *MSLN* promoter methylation in malignant pleural mesothelioma. Annual Meeting of the International Mesothelioma Interest Group, October 2014.
102. AR Cooper, G Lambert-Messerlian, E Eklund, J Dukes, R Colvin, A French, A White, and VS Ratts. Large prospective clinical study measuring ovarian reserve in females 4-50 years of age with autoimmune disease from 2008-2014: are “benign” therapies really safe? Annual Meeting of the American Society of Reproductive Medicine. Hawaii, October 2014.
103. EA Seidler, JS Rhee, E Eklund, G Lambert-Messerlian, AR Cooper. Like mother, like daughter? A comparison of anti-mullerian hormone levels in samples pairs of maternal serum and female neonatal cord blood. Annual Meeting of the American Society of Reproductive Medicine. Hawaii, October 2014. (Oral presentation)
104. JS Rhee, EA Seidler, E Eklund, G Lambert-Messerlian, AR Cooper. AMH values may be falsely lowered by storage conditions, assay processing and length of time stored. Annual Meeting of the American Society of Reproductive Medicine. Hawaii, October 2014.
105. Maredia HS, Lambert-Messerlian GM, McGarvey ST. Understanding the distribution and clinical features of polycystic ovaries using AMH in Samoan women. 12th Annual Meeting of AEPCOS Society, Kauai, Hawaii, October 22-23, 2014

106. Cantonwine DE, Meeker JD, Ferguson KK, Wilkins-Haug L, Lambert-Messerlian G, McElrath TF. Urinary phthalates increase PAPP-A levels early in pregnancy. Annual Meeting of the Society for Maternal Fetal Medicine, February 2015.
107. Richard G. Moore, M Craig Miller, Nicole Romano, Elizabeth Lokich, Katina Robison, Ashley Stuckey, Paul DiSilvestro, C.O. Granai, Geralyn Lambert-Messerlian. Analysis of HE4 expression in various epithelial ovarian cancers and LMP tumors. Annual Meeting of the Society for Gynecologic Oncologists, Chicago IL, March 2015.
108. ST McGarvey, G Lambert-Messerlian, RL Minster, O Buhle, H Maredia, S Viali, NL Hawley, R Deka, DE Weeks. Genome-wide association study of Samoan women's reproductive biomarkers. Human Biology Association Meeting, St Louis, MO, March 2015.
109. Lee J, Eklund E, Messerlian G, Butterfield K, Curran P, Bourjeily G. Effect of body mass index on serum progesterone levels in pregnant women. Women's Health 2015: The 23rd Annual Congress, Washington, DC, April 16-19, 2015.
110. Mohamad Irani, David Seifer, Richard Grazi, Devika Bhatt, Nitasha Julka, Bharati Kalgi, Sara Irani, Geralyn Messerlian, Reshef Tal. The Effect of Vitamin D on Anti-Mullerian Hormone, Clinical and Metabolic Parameters in Women with Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Trial. New York Obstetrical Society Meeting, NY April 14, 2015. (Oral presentation)
111. Lambert-Messerlian G, Kloza E, O'Brien B, Palomaki G. Introduction of a cell free (cf) DNA test for aneuploidy as part of routine prenatal care: Results of a structured patient survey in women having testing. Annual Meeting of the International Society for Prenatal Diagnosis. Washington DC, July 2015.
112. Kloza E, O'Brien B, Lambert-Messerlian G, Eklund E, Palomaki GE. Patient responses to cfDNA testing for aneuploidy in a general pregnancy population: preliminary results of the Rhode Island experience. National Society of Genetic Counselors Annual Education Conference Pittsburgh PA, October 21-24, 2015 (Oral presentation).
113. Palomaki GE, Kloza E, O'Brien B, Eklund E, Lambert-Messerlian G. Transitioning cfDNA testing for aneuploidy to a general pregnancy population: preliminary results of the Rhode Island experience. National Society of Genetic Counselors Annual Education Conference Pittsburgh PA, October 21-24, 2015.
114. Jennifer S. Graves, Roland Henry, Bruce Cree, Geralyn Messerlian, Ruth Greenblatt, Marcelle Cedars, Peter Bacchetti, UCSF Epic Team, Stephen L. Hauser, Jorge Oksenberg. Ovarian age is associated with gray matter volume and disability in women with MS independent of chronological age and disease duration. ACTRIMS Forum, New Orleans, Louisiana, USA, February 18-20, 2016. (Oral presentation)
115. O'Brien BM, Kloza E, Lambert-Messerlian G, Eklund E, Palomaki GE. Prenatal Sex Aneuploidy Screening in the General Risk Population Using cfDNA: Patient and Provider Experience in Rhode Island Annual Clinical Genetics Meeting. Tampa, Florida, March 8-12, 2016.
116. Eklund EE, Maggio L, Palomaki GE, Neveux LM, Lambert-Messerlian G. Serum follistatin related proteins for prediction of gestational diabetes. Annual Meeting of the Endocrine Society, Boston MA, April 1-4, 2016.

117. Kahn N, Messerlian G, Hodosy J, Celec P, Eklund E, Monteiro F, Bourjeily G. Oxidative and Carbonyl Stress in Pregnant Women with Obstructive Sleep Apnea. American Journal for Respiratory and Critical Care Medicine. 193: A6638, May 2016
118. Palomaki GE, Kloza EK, O'Brien BM, Eklund EE, Lambert-Messerlian GM. Prenatal cell free (cf)DNA screening in low risk pregnancies through primary providers: A demonstration project ISPD 20th International Conference on Prenatal Diagnosis, Berlin, Germany, 10 – 13 July 2016.
119. La'ulu SL, Lambert-Messerlian G, Palomaki GE, Straseski JA, Eklund EE, Soldin SJ, Haddow JE. Thyroid hormone measurements in pregnancy: Comparisons of immunoassays to mass spectrometry. Annual Meeting of the American Association of Clinical Chemistry, Philadelphia PA, August 2016. (Oral presentation, Outstanding Abstract Award)
120. Young J, Radwan R, Gannon S, Le J, Falcone K, Raju S, Benina N, Zhu L, Svensson N, Vanerhav K, Majnesjo K, Jones S, Peacock C, White N, Wheeler P, Li Z, Fermer C, Donaldson K, Eklund E, Lambert-Messerlian G. Lumipulse G HE4 assay for monitoring of patients with epithelial ovarian cancer. Annual Meeting of the American Association of Clinical Chemistry, Philadelphia PA, August 2016.
121. Radwan R, Falcone K, Raju S, Jones S, Gannon S, Le J, Nguyen M, Benina N, Fiedman C, Zhu L, Svensson N, Vanerhav K, Majnesjo K, Peacock C, White N, Wheeler P, Eklund E, Li Z, Young J, Fermer C, Donaldson K, Lambert-Messerlian G, Dickson D. A risk of ovarian malignancy algorithm (ROMA) derived from Lumipulse G HE4 and Lumipulse CA125II assays. Annual Meeting of the American Association of Clinical Chemistry, Philadelphia PA, August 2016.
122. Young J, Benina N, Le J, Feldman C, Zhu L, Falcone K, Raju S, Jones S, Wheeler P, Eklund E, Hunsaker J, Peacock C, White N, Li Z, Donaldson K, Lambert-Messerlian G, Genzen J, Grenache D, Radwan R, Dickson D. A Lumipulse G assay for quantitation of 25-OH vitamin D in human serum and plasma. Annual Meeting of the American Association of Clinical Chemistry, Philadelphia PA, August 2016.
123. Benina N, Gannon S, Feldman C, Le J, Falcone K, Raju S, Jones S, Peacock C, White N, Eklund E, Hunsaker J, Li Z, Genzen J, Lambert-Messerlian G, Grenache D, Radwan R, Young J, Dickson D. Lumipulse G TP-N assay for quantification of anti-TP antibodies in human serum and plasma. Annual Meeting of the American Association of Clinical Chemistry, Philadelphia PA, August 2016.
124. Kloza E, Palomaki GE, O'Brien B, Eklund EE, Lambert-Messerlian G. The impact of patient education on understanding of cfDNA screening among pregnant women in a general risk population: the Rhode Island experience. National Society of Genetic Counselors Annual Education Conference, Seattle, WA, Sep 28- Oct 1, 2016.
125. G Lambert-Messerlian, J Straseski, E Eklund, G Palomaki and J Haddow. Should blood samples be collected under fasting conditions for measurement of anti-mullerian hormone (AMH)? American Society for Reproductive Medicine. Salt Lake City, UT, October 2016.
126. J.E. Mitchell, M.C. Miller, R. Singh, G. Messerlian and R.G. Moore. The differential analysis of serum HE4 levels in epithelial ovarian cancer and other malignant tumors. Society for Gynecologic Oncology, National Harbor, MD, March 2017.
127. N. Benina, S. Gannon, C. Feldman, L. Zhu, S. Raju, M. Nguyen, K. Falcone, S. Raju, K. McMullen, D. Ziegler, N. White, E. Eklund, J. Hunsaker, P. Wheeler, J. Genzen, G. Lambert-Messerlian, D. Grenache, K. Donaldson, R. Radwan, J. Young, D. Dickson, Z. Vucetic. Quantitative Determination of

Thyroid Stimulating Hormone (TSH) in Human Serum by Lumipulse® G TSH-III Assay. AACC, San Diego CA, July 2017.

128. Blackman AM, Miller MC, Eklund E, Granai CO, Messerlian-Lambert G, Strongin R, Moore RG. The utility of additional ovarian cancer biomarkers to the dual marker combination of HE4 and CA125 for the detection of cancer. Society for Gynecologic Oncology, New Orleans, LA, March 2018.

129. S. Gannon, N. Benina, C. Feldman, S. Raju, M. Wang, K. Falcone, D. Ziegler, N. White, C. Peacock, J. Latham, K. Maddaloni, J. R. Genzen, G. Lambert-Messerlian, D. G. Grenache, K. Donaldson, R. Radwan, J. Young, S. Dolan, D. Dickson, C. Traynham. Quantitative Determination of Procalcitonin (PCT) in Human Serum by Lumipulse® G B•R•A•H•M•S PCT Assay. AACC, Chicago, July 2018.

130. Lambert-Messerlian G and Palomaki GE. Fewer women 35 and older choose serum screening. International Society for Prenatal Diagnosis, Belgium, July 2018.

131. Palomaki GE, Kalra B, Kumar T, Patel AS, Savjani G, Torchen LC, Dunaif A, Lambert-Messerlian GM, Kumar A. Adjusting anti-Müllerian hormone (AMH) levels for age and body mass index improves detection of polycystic ovary syndrome (PCOS). AEP COS Meeting, Sweden, September 2018.

132. Golenbock SW, Wise LA, Lambert-Messerlian GM, EE Eklund, Harlow BL. Association between history of depression and anti-müllerian hormone among late reproductive-aged women. American Society for Reproductive Medicine, Denver, Colorado, October 2018.

133. Dondik Y, Pagidas K, Eklund E, Ngo C, Palomaki G, Messerlian G. Angiogenic markers of placental function in egg donor IVF pregnancies. American Society for Reproductive Medicine, Denver, Colorado, October 2018.

134. L. Underhill, R. Tucker, K. Evans, B. Eklund, S. Park, G. Messerlian, B. Lechner. Serum Biglycan and Decorin as Potential Predictors of PPRM in Asymptomatic Women. Society for Reproductive Investigation, Paris, France, March 2019.

135. Wise LA, Wang TR, Schisterman EF, Harlow BL, Mumford SL, Messerlian G, Mikkelsen EM, Hatch EE. Oral contraceptive use and anti-müllerian hormone concentrations in premenopausal women: a pooled analysis of four cohorts. Society for Epidemiologic Research, Minneapolis MN, June 2019.

136. N. Benina, K. Falcone, S. Raju, S. Marcoon, J. Latham, K. Le, A. Calabro, M. Urbanski, S. Syjjongtian, U. Dahlen, C. Fermer, G. Lambert-Messerlian, E. Eklund, K. Donaldson, P. Wheeler, J. Genzen, J. Hunsaker, R. Radwan, S. Dolan, D. Dickson, C. J. Traynham. Validation of the Lumipulse® G Anti-Müllerian Hormone (AMH) Assay for Quantitative Determination of AMH in Human Serum and Plasma. Annual Meeting of the American Association for Clinical Chemistry, Anaheim CA, August 2019. #B-177.

137. Benina N, Falcone K, Raju S, Marcoon S, Le K, Wang M, Van der Cruyssen N, Vandijck M, De Decker B, Rombout A, Genzen J, Grenache D, Hunsaker J, Lambert-Messerlian G, Eklund E, Donaldson K, Wheeler P, Radwan R, Dolan S, Dickson D, Traynham CJ. The Lumipulse G whole parathyroid hormone (wPTH) assay: a fully automated method for quantitative determination of wPTH in human serum and plasma. Annual Meeting of the American Association for Clinical Chemistry, Anaheim CA, August 2019. #A-149.

138. Erdogan-Yildirim Z, Carlson JC, Pomer A, Hawley NL, Cheng H, Naseri T, Reupena SM, Deka R, Lambert-Messerlian G, McGarvey ST, Weeks DE, Minster RL, and the TOPMed Reproductive Health Working Group. Identification of susceptibility loci for reproductive traits in Samoan women. Annual Meeting of the Society for Human Genetics. Houston TX, Oct 2019.
139. Madison T Ortega, Lauren Carlson, John A McGrath, Margaret George, Geralyn Messerlian, Natalie D. Shaw. The role of intrinsic ovarian immaturity in anovulatory menstrual cycles among healthy girls. NIEHS Science Days, Research Triangle Park, NC, Nov 2019
140. A. Samborski, M.C. Miller, S. MacLaughlan, A. Jackson, E. Eklund, G. Lambert-Messerlian, R.G. Moore. Serum HE4 is a novel biomarker and alternative to CA125 for monitoring women with ovarian cancer. Society of Gynecological Oncology, Toronto, Canada, March 2020.
141. Blackman AM, Samborski A, Miller MC, Singh R, Kim KK, Turner R, Messerlian G, Moore RG Analysis of serum HE4 and CA 125 levels in uterine cancers subtypes. Society of Gynecological Oncology, Toronto, Canada, March 2020.
142. M Ortega, L Carlson, JA McGrath, T Kangarloo, JM Adams, P Sluss, G Messerlian, ND Shaw. AMH Is Higher Across the Menstrual Cycle in Early Post-Menarchal Girls than in Ovulatory Women. Annual Meeting of the Endocrine Society, San Francisco, CA, June 2020 (on-line).
143. Blackman AM, Samborski A, Miller MC, Singh R, Kim KK, Turner R, Messerlian G, Moore RGA novel predictive probability algorithm to determine risk for malignancy between uterine fibroids versus uterine sarcoma. American Society of Clinical Oncology, Chicago IL, May/June 2020.
144. A. Samborski, A. Blackman, Miller MC, E. Eklund, G. Messerlian, R.G. Moore. Biomarker lead time for predicting progression in women with ovarian cancer compared to imaging. American Society of Clinical Oncology, Chicago IL, May/June 2020.
145. Erdoğan-Yıldırım Z, Carlson JC, Zhang JZ, Pomer A, Hawley NL, Cheng H, Naseri T, Reupena MS, Deka R, Lambert-Messerlian GM, McGarvey ST, Weeks DE, Minster RL, and the TOPMed Reproductive Health Working Group. Genome-wide association study of high vs low risk polycystic ovary syndrome in Samoan women. Annual Meeting of ASHG, San Diego CA, Oct 2020.
146. Palomaki GE, Kloza EM, Eklund E, Messerlian G. The VALUE Study: External validation of the clinical validity of an automated cell free (cf)DNA screening test for Down syndrome. ISPD, virtual, June 2021.
147. Palomaki GE, Kloza EM, Eklund E, Messerlian G. External validation of the clinical validity and utility of an automated low cost cfDNA screening test for Down syndrome. AACC, Atlanta, GA, Sep 2021.
148. Kloza EM, Eklund EE, Lambert Messerlian G, Palomaki GE. Expanding access to prenatal cfDNA testing: validation of an automated non-NGS testing platform. NSCG, New Orleans, LA, Sep 2021.
149. Bai, A. Sanapo L., Bublitz M., Mehta, N., Lambert-Messerlian G., Catalano, P., Bourjeily G. Association between sleep disordered breathing and glucose metabolism in early pregnancy. Chest, Orlando, FL, Oct 2021.
150. Lauren A. Wise, Amelia K. Wesselink, Erica E. Marsh, Antonia M. Calafat, Ellen M. Mikkelsen, Elizabeth E. Hatch, Geralyn M. Lambert-Messerlian. Perfluoroalkyl and polyfluoroalkyl substances and anti-mullerian hormone concentrations in two preconception cohort studies. Annual Scientific Meeting of the Society for Reproductive Investigation, Denver CO, Mar 2022 (Oral presentation)

151. G. Bourjeily, L. Sanapo, M. Guillen, T. El-Zarif, A. Avalos, A. Aldana, T. Sequeira, C. Felber, G. Lambert-Messerlian. A longitudinal study of impulse oscillometry and respiratory mechanics in pregnancy: implications for respiratory disorders. Chest Congress, Bologna, Italy, June 2022

152. Hardy EJ, Palomaki GE, Schneider RJ, Daghfal D, Sung CJ, Lambert-Messerlian GM. SARS-CoV-2 Seroprevalence in Rhode Island pregnancies in early 2020. Annual Meeting AACC, Chicago IL, July 2022.

INVITED PRESENTATIONS

1. January 1993 Massachusetts General Hospital Reproductive Science Research Rounds
Boston, Massachusetts
Alpha Inhibin Proteins in Human Serum
2. May 1994 Foundation for Blood Research
Scarborough, Maine
Physiology of Inhibin and its Subunits
3. November 1995 Rhode Island College Biology Department Colloquium
Providence, Rhode Island
Inhibin in Reproductive Physiology
4. August 1996 Women and Infants Hospital Pathology Department Research Rounds
Providence, Rhode Island
Physiology and Biochemistry of Inhibin
5. May 1997 Chiron Diagnostics
Walpole, MA
Inhibin in Women: Physiology and Clinical Applications
6. March 1998 Society for Gynecologic Investigation
Atlanta, Georgia
Inhibin: An Early Marker for Ovarian Reserve?
7. May 1998 Clinical Laboratory Science Society
Providence, Rhode Island
Hormones in Gynecologic and Prenatal Testing
8. May 1998 Memorial Hospital Obstetrical Grand Rounds
Pawtucket, Rhode Island
Serum Screening with the Quad Test
- 9. September 1998 Oxford Brookes University
Oxford, England
Inhibin A in Maternal Serum Screening**
10. October 1998 Brown University Pathology Department Research Rounds
Providence, Rhode Island
Activin A in Epithelial Ovarian Cancer
11. September 1999 Society of Perinatal Pathology
Providence, Rhode Island
Advances in Prenatal Screening

12. April 2000 New York University Pathology Grand Rounds
New York, New York
Advances in Prenatal Screening II
13. April 2000 Clinical Laboratory Science Society
Providence, Rhode Island
Hormones in Gynecologic and Prenatal Testing
14. April 2000 Women's Health Research Exhibit
U.S. Senate, Washington, DC
Fetal Study and Evaluation Project (FASTER)
- 15. June 2000 Session Chair - Endocrine Society Meeting
Toronto, Canada
Recent Advances in the Regulation of the Inhibin/Activin System in
Reproduction**
16. November 2001 Women and Infants Hospital Pathology Department Research Rounds
Providence, Rhode Island
Role of Activin in Human Palate Development
17. July 2002 American Association of Clinical Chemistry
Orlando, Florida
Inhibins and Activin in Ovarian Cancer
18. March 2003 Prenatal Screening for Down Syndrome: Introducing the Integrated Test
Providence, Rhode Island
Epidemiological monitoring of NT measurement
- 19. July 2003 5th World Symposium on Inhibins, Activins and Follistatins
Sienna, Italy
Inhibins and Activins in Human Fetal Abnormalities**
20. May 2004 Grand Rounds, Dept Genetics, New England Medical Center
Boston, Massachusetts
Inhibin and activin in Down syndrome and other fetal abnormalities
21. June 2005 Annual Meeting of the Endocrine Society
San Diego, CA
Maternal serum screening for Down syndrome: clinical and basic aspects
22. November 2005 Brown University, Pathology Department Rounds
Providence, RI
Update on prenatal screening tests
- 23. May 2006 International Down Syndrome Screening Group
Amsterdam, Netherlands
Monitoring of Nuchal Translucency Measurements
and Effects of ART on Screening Markers**
24. March 2007 University of Massachusetts/ Worcester
Grand Rounds

- Advances in Prenatal Screening
25. March 2007 Second international Conference on the Integrated test
Providence, Rhode Island
Serum Integrated Screening and NT Quality Assurance
26. July 2007 American Association for Clinical Chemistry
San Diego, CA
Hormone measurements to determine ovarian reserve
- 27. May 2008 International Down Syndrome Screening Group
Vancouver, Canada
Advances in Inhibin Immunoassay**
28. July 2008 American Association for Clinical Chemistry
Washington, DC
Testing for ovarian reserve
29. July 2009 Annual Meeting of the Endocrine Society
Washington DC
New therapeutic & investigational approaches to female reproductive disorders
Session Chair
30. July 2009 American Association for Clinical Chemistry
Chicago, IL
Routine and emerging markers of ovarian reserve
31. April 2010 Northeast Region Conference and Exhibition (NERCE)
Boxborough, MA
Progress in prenatal screening for Down syndrome
32. July 2010 American Association for Clinical Chemistry
Anaheim, CA
Routine and emerging markers of ovarian reserve
33. Sept 2010 WIH Ob-Gyn Faculty Research Seminar
Second trimester serum markers for prediction of preeclampsia
34. March 2011 Northwestern University
Endocrinology Grand Rounds
Serum screening to predict preeclampsia
35. July 2011 American Association for Clinical Chemistry
Atlanta, GA
Emerging tests in prenatal screening (oral session moderator)
and
Prenatal screening: Fundamentals and Innovations (workshop)
36. July 2012 American Association for Clinical Chemistry
Los Angeles, CA

- Contemporary prenatal testing for Down syndrome (short course moderator)
and AMH: A marker of ovarian reserve
37. July 2013 American Association for Clinical Chemistry
Houston, TX
State of the art testing for female cancers (moderator)
38. June 2014 New England Association of Gynecologic Oncologists
Newport, RI
Basic Science Studies of Ovarian Cancer (moderator)
39. July 2014 American Association for Clinical Chemistry
Chicago, IL
AMH: Improved laboratory assessment of ovarian reserve
40. July 2014 Memorial Hospital
Pawtucket, RI
Prenatal screening for Down syndrome using ccfDNA
41. Feb 2015 Northeast AACC
Waltham, MA
Laboratory assessment of ovarian reserve: AMH
42. Apr 2015 AACC Professional Practice Course
Philadelphia, PA
Endocrinology of the female reproductive axis
and Prenatal Screening: Serum or DNA?
- 43. May 2015 Antenatal Prenatal Screening Course
London, UK
Course faculty member**
44. Sep 2015 Neonatology Rounds
Women and Infants Hospital
Serum markers to predict preeclampsia
45. Aug 2016 American Association for Clinical Chemistry
Philadelphia, PA
Prospective cfDNA-based prenatal screening in the general pregnancy
population offered by primary obstetrical care providers in Rhode Island
46. Nov 2016 Northeast Section of AACC
Waltham, MA
Prenatal Screening for Aneuploidy with cfDNA
47. Dec 2016 Women and Infants
Providence, RI
Ob-Gyn Rounds
Contemporary prenatal screening for aneuploidy
48. Dec 2016 Mayo Medical Laboratory

- Rochester, MN
cfDNA based prenatal screening in the general pregnancy population
49. Feb 2017 AACC
Webinar
Cell free DNA screening in the general pregnancy population
50. Mar 2017 NPIC
Webinar
Contemporary screening for Down syndrome with cfDNA
51. July 2017 AACC
Diagnostic Lab Testing for Infertility and PCOS (Moderator)
San Diego, CA
52. Aug 2017 AACC
Multiple marker screening for pregnancy complications
San Diego, CA
53. Aug 2017 AACC
Counting on AMH assays (Brown Bag workshop)
San Diego, CA
54. Oct 2018 Cambridge conference
VALUE study
Boston, MA
55. Feb 2019 Ansh Labs
Prenatal screening for preeclampsia
Webster, TX
56. Feb 2019 Women and Infants Division of Ob Medicine
Screening for early delivery associated with preeclampsia
Providence, RI
57. Apr 2019 Northeast Section of AACC
Prenatal screening for preeclampsia: the time has come
Waltham MA
58. Aug 2019 Ansh Labs Dinner Symposium
AMH levels in women
Anaheim, CA
59. Mar 2020 Women and Infants Division of Ob Medicine
Prenatal screening for preeclampsia
Providence, RI
60. Jun 2020 American Society for Clinical Pathology (ASCP)
Anti-müllerian hormone: biology, immunoassays, and clinical applications
On demand webinar

61. Nov 2021 Philippine Society of Pathologists
Prenatal laboratory testing
Virtual conference
62. June 2022 European Human Genetics Conference
A simplified method of cfDNA screening
Vienna, Austria (virtual)
63. June 2022 Annual Meeting of the Endocrine Society
Maximizing the mentor and mentee relationship (panelist)
Atlanta, GA
64. Nov 2022 9th World Congress on Controversies in Preconception, Preimplantation and
Prenatal Genetic Diagnosis (CoGEN)
A simplified method of cfDNA screening
Online Congress
65. Nov 2022 Symposia-bianco: An ISUOG Advanced Course
Hot topics & controversies in fetomaternal medicine, 3rd edition
A simplified method of cfDNA screening
Genova, Italy (virtual)

GRANTS

1. 1989-1991 Principal Investigator
Predoctoral Fellowship
National Institute of Mental Health
MH-09812
Opioid regulation of LH secretion in the ferret
2. 1991-1994 Postdoctoral Fellowship
NRSA Institutional Training grant
T32-HD07396
Alpha inhibin processing
3. 1993-1995 Co-investigator
National Institute of Health
U54 - National Center for Infertility Research
Inhibin physiology in the human
\$1,721,792
4. 1994-1997 Co-investigator
National Institute of Health
RO1-HD31894
Role of inhibin in oocyte maturation
\$1,596,043
5. 1997-1998 Co-Principal Investigator
Women and Infants Hospital - Department of Obstetrics and Gynecology
Antiphospholipid antibodies in women undergoing IVF
\$3900

6. 1997-1998
Co-Principal Investigator
Women and Infants Hospital - Department of Obstetrics and Gynecology
Alpha inhibin in ovarian cancer
\$9100
7. 1999-2005
Co-investigator testing site (HD38652-Canick)
National Institute of Child Health and Development (D'Alton PI)
First and second trimester evaluation of risk of aneuploidy (FASTER)
\$1,010,338
8. 2002-2005
Principal Investigator
National Institute of Dental and Craniofacial Research
1 RO3 DE 14002-01 A1
Inhibin/activin family in human craniofacial development
\$100,000
9. 2004
Co-investigator
Impact of Adolescent Pregnancy on Poor Birth Outcomes
Brown University Seed Grant (M. Phipps, MD, PI)
\$100,000
10. 2004-2005
Principal Investigator
National Institute of Child Health and Development
Subcontract (Lambert-Messerlian)
Hypothyroidism and perinatal outcome
RO1-HD 038652-03S6 (D'Alton)
\$364,002
11. 2006-2008
Co-principal investigator
Inhibin B levels in premenstrual dysphoric disorder
National Institute of Health
R21 MH074914-01A1 (S. Hartlage, PI)
\$275,000
12. 2008-2010
Co-investigator
A model statewide trial to detect and treat maternal hypothyroidism
National Center for Chronic Disease Prevention (CDC)
(JE Haddow, PI)
\$449,968
13. 2009-2012
Investigator
RNA study to determine Down syndrome risk
Sequenom
(Jacob Canick, PI)
\$ 6,540,265
14. 2009-2014
Investigator
The Development of an Assay for the Early Detection of Ovarian Cancer
NIH R01 CA136491 (Moore, PI)
\$1,680,124

15. 2010 Principal Investigator
Susceptibility genes for PCOS in Samoan Women
Brown University (WIH Center of Excellence Seed Grant)
\$20,000
16. 2013-2016 Investigator
DNA First: Primary Screening for Down syndrome by Maternal Plasma DNA
Natera (Palomaki, PI)
\$400,000
17. 2014-2019 Co-Investigator/Consortium PI
Placental role in mediating adverse outcomes in obstructive sleep apnea
NIH 1R01HD078515-01A1 (Bourjeily, PI)
\$24,041
18. 2015 Pilot study Co-investigator
Sex specific aging and multiple sclerosis phenotype
National MS Society (Graves, PI)
19. 2016-2019 Co-Investigator/Consortium PI
De novo predictors of OSA
NIH R01 HL130701 (Bourjeily, PI)
\$48,639
20. 2016-2019 Co-investigator
Validation of low-cost aneuploidy screening
Perkin Elmer (Palomaki PI)
\$1,500,000
21. 2016-2019 Co-investigator
The role of biological aging on progression in MS
National Multiple Sclerosis Society (Graves PI, UCSD)
22. 2018-2020 Co-investigator
Daily-level Analysis of Ovarian Hormones, Smoking, and Anxiety
NIH 1R21DA045182-01A1 (Farris PI, Rutgers)
\$10,000
23. 2019-2021 Co-investigator
Reprise: Retrospective study of screening for preeclampsia
Perkin Elmer (Palomaki, PI)
\$200,000
24. 2019-2020 Co-investigator
Vitamin D levels and preeclampsia
Yale University (Seifer)
\$37,000
25. 2020-2021 Principal investigator
Rate of Covid exposure in pregnant women in RI
Abbott Labs
\$25,000

26. 2020-2022 Co-investigator
Step-up: demonstration project for first trimester preeclampsia screening
Perkin Elmer (Palomaki/Lambert-Messerlian, PI)
\$800,000
27. 2022 PI
Validation of unconjugated estriol for prenatal screening
Beckman Coulter
\$50,000

CONTRACTS

1. 1995 AFP immunoassay validation
Sanofi Pasteur Diagnostics
2. 1995-1997 Urinary UGP for maternal screening
Ciba-Corning
3. 1998-2006 Consultant
Diagnostic Systems Laboratories, Inc., TX
4. 2002-2004 Study of PP13 levels in complications of pregnancy
Diagnostic Technologies, Ltd., Israel
5. 2004-2005 Consultant
Protein markers for abnormal pregnancy
Proteogenix, Inc., Seattle, WA
6. 2007-2009 Consultant
Beckman Coulter Inc.
7. 2007-2008 Access inhibin A method correlation and median study
Beckman-Coulter, Inc.
8. 2008-2009 Access PAPP-A method correlation and median study
Beckman-Coulter, Inc.
9. 2008-2009 Second trimester markers to predict pre-eclamptic pregnancy
Beckman-Coulter, Inc.
10. 2009 Validation of estriol assay on Immulite 2000
Siemens Diagnostics
11. 2010 Validation of EPO assay on Immulite 2000
Siemens Diagnostics
12. 2011 Laboratory testing protocol for Access Immunoassay systems
Beckman-Coulter, Inc.
13. 2011-2012 AFP assay validation study
Abbott Laboratories

14. 2011-2014	ROMA precision study I and II and III Fujirebio Diagnostics
15. 2012	Galectin precision study Fujirebio Diagnostics
16. 2012	Multiple marker testing for ovarian cancer Beckman-Coulter, Inc.
17. 2013	Validation of WHO 5 hCG calibration Beckman-Coulter, Inc.
18. 2013	i-Stat cartridge for hCG testing Abbott Laboratories
19. 2014	Methotrexate precision study I and II and III Fujirebio Diagnostics
20. 2014	BNP method comparison study Fujirebio Diagnostics
21. 2014-2015	CA 125 method comparisons Morphotek Diagnostics
22. 2014	Lumipulse CA 125 precision and comparison studies Fujirebio Diagnostics
23. 2015	Therapeutic interference study Fujirebio Diagnostics
24. 2015	Vitamin D precision study Fujirebio Diagnostics
25. 2015	TP-N (syphilis) precision study Fujirebio Diagnostics
25. 2016	Procalcitonin precision and method comparison Fujirebio Diagnostics
26. 2016	Fertility markers precision and method comparison Fujirebio Diagnostics
25. 2017	CA 15-3 Precision Fujirebio Diagnostics
25. 2017	CA 19-9 Precision Fujirebio Diagnostics
25. 2018	C-peptide Precision Fujirebio Diagnostics

- | | |
|----------|--|
| 26. 2018 | PTH Precision and Method Comparison
Fujirebio Diagnostics |
| 27. 2018 | AMH Precision and Reference range
Fujirebio Diagnostics |
| 28. 2020 | B-Amyloid Precision
Fujirebio Diagnostics |

UNIVERSITY TEACHING ROLES

Courses

- | | |
|-----------|--|
| 2001-2003 | Instructor
Biol 0300: Endocrinology
Faculty Instructor for Reproductive Endocrinology section (1/3 course) |
| 2004–2016 | Course leader
Biol 0300: Endocrinology |
| 2010 | Course leader
Topics in Pathobiology Seminar BIOL 2840H
Human Reproduction: Biology and Toxicology |
| 2011-2021 | Lecturer
Alpert Medical School of Brown University
BIOL 3642 IMS-I: Scientific Foundations of Medicine
Prenatal screening and diagnosis |
| 2018 | Panelist
Lifting the Voices of Women in Science and Medicine
Involvement in Professional Societies and National Organizations
Alpert Medical School of Brown University |
| 2020 | Panelist
Rhode Island Women’s Health Summit
Sex and Gender, Medical Research and our Community
Alpert Medical School of Brown University |

Undergraduate student research

- | | |
|-----------|--|
| 1996 | Kirstin Woo (UTRA recipient)
Urinary gonadotropin peptide assay development |
| 1997-1999 | Dori Rausch
Participation in maternal serum screening |
| 1998-1999 | Valerie Plati
Serum markers of pre-eclampsia |
| 2000 | Mitra Shah-Hosseini
Thyroid hormone levels in the first trimester pregnancy |

2002-2004	Lealah Pollack (UTRA recipient) Serum markers of early pregnancy viability
2005	Kaitlin Masaire Inhibin in the brain: Role in mood disorders related to reproductive cycles
2005-2008	Gavin Myers Levels of inhibin B in men with proven fertility and with low sperm count
2006-2007	Yelena Dondik MIS as a marker of ovarian reserve
2007-2009	Miles Miller Inhibin expression in human brain
2008	Marisa Roberts Obesity and Infertility in Samoan Women
2008-2009	Sam Urlacher Biologic markers of infertility in Samoan Women Senior Prize in Biology
2011	Rubina Ratnaparkhi Assessment of fertility in Samoa
2012	Stephanie Lee Effects of obesity on fertility in Samoan Women
2012-2015	Hasina Maredia Angiogenic markers of pre-eclamptic pregnancy and Further study of reproductive function in women from Samoa Awards: Royce Scholarship Ruth and William Silen Award (Harvard New England Science Symposium, poster second prize) Senior Prize in Biology
2013-2014	Ava Runge Relationship of thyroid hormone levels and gestational diabetes
2017-2018	Christina Ngo HAPO sample analysis of thyroid hormone levels
2021-2022	Jade Ashley May Validation of improved Vanadis cfDNA screening test
2022	Jennifer Hardy (URI) Laboratory methods internship

Graduate student research

2008-2011	Jeena Santos Ahmed, MS Thesis Committee Member Pathobiology Department
2014-2018	Nicole Romano, PhD Thesis co-advisor University of Rhode Island Biomarkers of ovarian cancer
2018-2019	Grace O'Brien, MS Thesis co-advisor Epidemiology, Brown University AMH levels in Samoan Women
2019-2021	Lindsay Schneider, PhD Thesis committee member Brown Bio Medical Engineering (Dr. Tripathi) Microfluidic platform for targeted genomic amplification in PGD
2022	Yasmin Karasu, MS Thesis committee member Brown Bio Medical Engineering (Dr. Tripathi) Comparative analysis of deep learning models for cervical cancer diagnosis
2022	Zeynep Erdogan-Yildirim Project collaborator and advisor University of Pittsburg Genetic analysis of PCOS in women from Samoa

Mentorships

1996-2000	Brown University Women in Science Mentor
2003-2005	Society for Women in Endocrinology
2020	Natalie Banet, MD
2021-	Adina Badea, MD

HOSPITAL AND OTHER TEACHING ROLES

1993-1996	Rhode Island College Physiology Instructor
1996-present	Pathology Department Resident/ Fellow Training Program Supervise a one-week rotation in laboratory

1996-2000	Brandeis University Laboratory training for Genetic Counseling students
2003-2012	Annual lecture RI School of Cytotechnology Reproductive Endocrinology and Infertility in Women and Men
2005-2013	Course faculty (annual 3 ½ day course) Prenatal screening: Fundamentals and Innovations Providence, RI or Portland, ME
2011	Sara Lawrence College, NY Genetic Counseling Workshop Prenatal Screening: principles and practice

Resident and fellow research

1995-1996	Wenxin Zheng, MD Pathology Department Fellow Inhbin subunit expression in ovarian cancer tissues
1996-1998	Maureen Phipps, MD Department of Obstetrics and Gynecology Multiple marker testing for early pregnancy viability
1998-1999	Steve DePasquale, MD Womens' Oncology Fellow Inhbin/activin subunit gene expression in ovarian cancer
2000	H. Yamamoto, MD University of Sapporo, Japan Collagen peptides in preeclamptic pregnancy
2000-2002	Michael Plevyak, MD Department of Obstetrics and Gynecology – MFM Activin A levels in pregnancy with preterm labor
2001	Tom Lee, MD Department of Obstetrics and Gynecology - MFM Fetal cell analysis in aneuploid pregnancy
2002	Tom Wataganara, MD Department of Obstetrics and Gynecology - Tufts Fetal cell analysis in trisomy 18 and 13
2001-2002	Antonio Farina, MD, PhD University of Bologna, Italy Multiple marker testing in pregnancy
2001-2003	Karen Fish, MD

Department of Obstetrics and Gynecology – Reproductive Endocrinology
Use of serum CA 125 levels to predict IVF outcome

2002-2004 Phillip Pan, MD
New England Medical Center
Cell free fetal DNA levels in IVF pregnancy

2003-2004 Tamara Takoudes, MD
Department of Obstetrics and Gynecology - MFM
TPO as a marker of preeclamptic pregnancy

2003-2004 Talia Silberstein, MD
Department of Obstetrics and Gynecology – Reproductive Endocrinology
Use of serum MIS levels to predict IVF outcome

2004-2005 Adam Urato, MD
New England Medical Center
Relationship of maternal fetal cell levels and smoking

2004-2005 Michelle Russell, MD
Department of Obstetrics and Gynecology - MFM
Effect of elevated maternal serum AFP levels on fetal cell DNA

2008-2009 Neeta Vora, MD
New England Medical Center
Relationship of maternal fetal cell and serum marker levels

2009 Barbara O'Brien, MD
MFM Fellow
Maternal serum screening in fetuses with single umbilical artery

2009-2010 Nicole Sprawka, MD
MFM Fellow
AFP in type II diabetic pregnancies

2010 Jing Zhang, MD
Visiting Fellow
Effect of smoking on prenatal screening markers

2010-2013 Nada Kavar, MD
Fellow in Women's Oncology
MT19C effects on endometrial cancer

2016 Elizabeth Lockich, MD
Fellow in Women's Oncology
Thesis Reviewer
HE4 Expression is Associated with Hormonal Elements

2018-2020 Jenna Menella, DO
Fellow in Neonatology
Thesis Reviewer
Biglycan and decorin levels in normal pregnancy and PPRM

11/21/22